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Abstract 
Sepsis causes injury and dysfunction of pulmonary microvascular endothelial cells 
(PMVEC), leading to pulmonary edema. Metalloproteinases, are associated with 
inflammation and tissue damage, and their regulation by tissue inhibitors of 
metalloproteinases (TIMPs) may protect against septic PMVEC dysfunction. Thus, I 
hypothesize that murine septic PMVEC barrier dysfunction is due to disruption of the 
balance between metalloproteinases and TIMPs leading to increased metalloproteinase 
activity. 
PMVEC were isolated from wild type (WT) and Timp3-/- mice. Timp and 
metalloproteinase mRNA expression was altered under septic conditions and this was 
associated with increased metalloproteinase activity. Global metalloproteinase inhibitors BB-
94 and TAPI-2 reduced albumin and dextran flux across septic PMVEC. Further, Timp3-/- 
PMVEC had less cell surface intercellular adhesion molecule (ICAM) 1 vs. WT PMVEC, 
which was associated with significantly impaired neutrophil-PMVEC adhesion. 
Thus, my data suggest TIMPs may protect against septic PMVEC barrier dysfunction, 
at least partly, through direct inhibition of metalloproteinase activity. 
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Chapter 1  
1 Introduction 
1.1 Sepsis 
Sepsis is life-threatening organ dysfunction caused by a dysregulated host 
response to infection [1]. It is a common and important clinical problem associated with 
significant morbidity and mortality, and in North America, approximately one million 
cases of sepsis occur annually, leading to severe sepsis 40% of the time and 300, 000 
deaths [2]. Additionally, sepsis remains the leading cause of death in intensive care units 
(ICU). Sepsis also presents a significant economic burden as it consumes up to 45% of 
total ICU costs in the United States, or $24 billion annually [3,4]. Morbidity and 
mortality in sepsis are largely due to multiple organ dysfunction and failure, most 
commonly in the pulmonary, renal, and cardiac systems [3,5,6]. Despite intensive basic 
and clinical research, treatment of sepsis and related organ dysfunction consists largely of 
supportive care (i.e. antibiotics and intravenous fluids [IV]), with no specific therapy 
available for the treatment of systemic inflammation or resulting cellular and organ injury 
[7]. 
 Part of this dysregulated response is persistent systemic inflammation, causing 
major pathophysiological changes, including increased microvascular permeability 
leading to organ edema, damage, and dysfunction distant to the site of infection. Septic 
organ dysfunction is characterized by the activation and dysfunction of microvascular 
endothelial cells (MVEC), leading to a loss of microvascular barrier function [8]. In 
addition, septic inflammation is characterized by the activation of both circulating 
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(polymorphonuclear leukocyte [PMN]) and tissue-resident inflammatory cells 
(macrophages), as well as the enhanced activity of soluble inflammatory mediators, 
including lipopolysaccharide (LPS) and various cytokines (e.g. tumour necrosis factor 
[TNF] α, interleukin [IL] 1β, interferon [IFN] γ) [8]. 
1.2 Acute Respiratory Distress Syndrome 
Acute respiratory distress syndrome (ARDS) is a critical pulmonary illness 
characterized by increased pulmonary vascular permeability, which ultimately leads to 
severe pulmonary edema, increased lung weight, and loss of aerated lung tissue [9]. 
ARDS is triggered by direct pulmonary insults, such as gastric aspiration, smoke 
inhalation, and pneumonia, or by indirect insults, such as sepsis, pancreatitis, and trauma 
[10]. ARDS is also characterized by the activation of alveolar macrophages as well as the 
influx of circulating neutrophils, resulting in the enhanced production and release of 
inflammatory mediators including pro-inflammatory cytokines, oxidants, and proteases, 
ultimately leading to hypoxemia and potentially, death [11]. Persistent inflammation 
results in injury and dysfunction of the pulmonary microvasculature, which is 
characterized by a loss of structural integrity and increase in barrier permeability [11,12]. 
The disruption of junctions between adjacent pulmonary MVEC (PMVEC), specifically 
adherens junctions comprising vascular endothelial (VE)-cadherin, contributes to this 
pathology [10]. This results in the accumulation of protein-rich edema in the interstitial 
space, which ultimately crosses the injured epithelial barrier into the alveoli, impeding 
proper gas exchange and oxygenation. 
Despite advances in understanding ARDS, effective pharmacologic interventions 
shown to improve patient outcomes remain lacking [10]. While mortality rates associated 
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with ARDS have decreased recently due to improvements in mechanical ventilation and 
fluid management, mortality rates remain at approximately 30% [10]. Further, surviving 
patients deal with long-term pulmonary complications like persistent inflammation and 
fibrosis leading to an impaired quality of life [10].  
1.3 Microvascular Endothelial Cells 
The inner lining of all blood vessels consists of a monolayer of endothelial cells 
(EC), which serves as a selectively permeable barrier between the circulation and 
surrounding tissue [13–16]. In addition to the endothelial monolayer, blood vessels are 
comprised of multiple layers of smooth muscle cells, connective tissue, and pericytes 
[17]. However, capillaries, which are the smallest of all blood vessels, consist only of the 
single endothelial monolayer [17]. The microvasculature, includes the arterioles, 
capillaries, and postcapillary venules [17].  
The EC is a multifunctional cell. These functions include regulation of 
angiogenesis, the maintenance of a nonthrombogenic barrier, and the modulation of 
blood flow and vascular resistance. Further, EC mediate host immune responses via 
release of pro- and anti-inflammatory mediators, such as cytokines and chemokines, as 
well as regulation of leukocyte adhesion to the endothelial surface via changes in 
expression of surface adhesion molecules [15,17,18]. However, the primary role of EC is 
to act as a selectively permeable barrier between the contents of the vasculature and the 
surrounding tissue. In order to control the substances passing through the semi-permeable 
layer, EC have selective transport systems to target specific substrates. For example, 
larger substrates are thought to pass through the endothelial barrier membrane via a 
transcellular route mediated by caveolae [19].  
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1.3.1 MVEC Barrier Function 
Inter-MVEC adherens and tight intercellular junctions are required for the 
establishment and maintenance of MVEC barrier function [13,14,16,20–23]. However, 
dynamic control of endothelial permeability, which occurs through both paracellular and 
transcellular pathways, does allow for the regulated exchange of plasma proteins, solutes, 
and liquid between the vasculature and surrounding tissues [13,14,16,20–23]. The 
paracellular pathway consists of transport through the intercellular space between 
adjacent EC, whereas the transcellular pathway, also known as transcytosis, consists of 
active receptor-mediated transport through the cell itself [13,14,16,17]. Under basal 
conditions, only small molecules (e.g. ions) cross the endothelial barrier through the 
paracellular pathway [13,17]. Larger macromolecules are actively transported through 
membrane receptor/vesicle-mediated transcytosis [13,16,17,24].  
1.3.2 Regulation of MVEC Barrier Function 
Interaction of adjacent EC through adherens and tight intercellular junctions is the 
key mechanism regulating microvascular endothelial permeability [13,14,16,20–23]. 
These transmembrane junctional structures are comprised of multiple cell surface 
proteins, including VE-cadherin within adherens junctions, and the claudins and 
occludins within tight junctions [13,14,16,20,21,23].  
In addition to inter-MVEC interaction, microvascular permeability is also thought 
to be regulated by a mesh-like matrix, known as the glycocalyx, found on the luminal 
surface of the endothelial monolayer [13,25]. The glycocalyx is made up of glycoproteins 
and proteoglycans, including syndecans and glypicans, in addition to glycosaminoglycans 
(GAGs) [13,17,25]. Interestingly, the ability of the glycocalyx to facilitate maintenance 
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of a semi-permeable barrier to fluid and proteins may not occur in all microvascular beds 
(i.e. pulmonary microvasculature) as degradation of the glycocalyx was not associated 
with increased albumin flux or edema within the lung [26]. The glycocalyx is also 
involved in the regulation of circulating leukocyte-MVEC interactions such as trans-
MVEC migration [13,25]. 
The extracellular matrix (ECM) is also known to be a structural component 
required for the maintenance of endothelial barrier integrity. EC bound to the ECM are 
generally quiescent, as activation of integrins on the basolateral surface of EC following 
binding to the ECM generates signals that stabilize adjacent cell-cell and cell-ECM 
adhesions, which are vital to the formation and preservation of an endothelial barrier 
[27]. Thus, both the glycocalyx and the ECM are critical to establishing and maintaining 
endothelial integrity and barrier function. 
1.4 MVEC Dysfunction 
Dysfunction of the microvasculature under conditions of inflammation or 
infection is central to the resulting organ injury, dysfunction, and failure. This 
microvascular dysfunction is primarily characterized by activation and dysfunction of 
MVEC, leading to a loss of microvascular barrier function as well as upregulation of cell 
surface leukocyte receptors and upregulation of pro-thrombotic pathways 
[13,14,20,21,28,29]. Importantly, this dysfunction results in increased tissue 
inflammation and edema due to enhanced adhesion and diapedesis of leukocytes as well 
as increased microvascular permeability, both of which can lead to organ dysfunction and 
failure [13,14,20,21,28,29].  
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EC dysfunction occurs under many different conditions, including but not limited 
to local tissue injury, infection, and sepsis, but is also a hallmark of vascular diseases 
such as atherosclerosis. Within the setting of injury and/or infection, MVEC dysfunction 
is initiated by the interaction of MVEC with circulating blood components, including 
PMNs and soluble inflammatory mediators (e.g. bacterial products like LPS, or cytokines 
like TNF). In fact, MVEC dysfunction following injury or infection is highly PMN-
dependent [8,30–33]. There are several mechanisms of PMN-dependent cell/tissue injury. 
These include physical interaction (e.g. PMN-MVEC adhesion), release of reactive 
oxygen species (ROS), proteases/peptides (e.g. metalloproteinases), pro-inflammatory 
cytokines/chemokines, and cytotoxic neutrophil extracellular traps (NETs) [33,34]. 
1.4.1 Features of MVEC Dysfunction 
The primary features of MVEC dysfunction are the loss of MVEC barrier 
function and the increased PMN-MVEC interaction. The loss of MVEC barrier function 
is mediated through several mechanisms, including but not limited to disassembly of 
inter-MVEC adherens and tight junctions due to cleavage or modification of membrane 
junctional proteins; gap formation due to actin cytoskeleton rearrangement and 
microtubule-dependent MVEC contraction; activation of trans-MVEC transport systems; 
and MVEC death [21,22,35]. Enhanced PMN-MVEC interaction is associated with 
increased PMN recruitment out of the vasculature into tissues, and is thought to be 
dependent on a number of factors, including but not limited to increased release of pro-
inflammatory cytokines and chemokines, upregulation of MVEC cell surface leukocyte 
receptors, and shedding of the glycocalyx [36,37].  
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1.4.2 Mechanisms of MVEC Barrier Dysfunction 
 MVEC activation by inflammatory cytokines and leukocytes leads to increased 
MVEC permeability, and this increased permeability is primarily due to loss of inter-
MVEC junctions and MVEC retraction [13,14,20,21,28,29]. As VE-cadherin is critical to 
the formation of MVEC adherens junctions, modifications of its structure along with its 
associated intracellular catenins, including p120, - and -catenin, significantly 
attenuates barrier integrity [13,14,16,20,21,23,38]. For example, enhanced barrier 
permeability is correlated with tyrosine phosphorylation of the VE-cadherin/catenin 
complex [13,14,16,39].  
 Activation of MVEC by pro-inflammatory cytokines (e.g. TNFα) has also been 
shown to induce loss of barrier function by promoting cleavage of VE-cadherin and the 
generation of a soluble extracellular fragment [13,16,40,41]. This VE-cadherin cleavage 
appears to be at least partially dependent on tyrosine phosphorylation of the VE-
cadherin/catenin complex by several kinases (i.e. Protein Kinase C [PKC] and p38 
mitogen-activated protein kinase) [13,16,40,41]. Finally, thrombin has been found to bind 
protease-activated receptor (PAR) 1 on the MVEC surface, and promote barrier 
dysfunction by increasing cytosolic Ca2+ concentrations leading to PKCα-dependent VE-
cadherin phosphorylation and subsequent internalization [13,16,42]. Collectively, these 
studies illustrate the complex intercellular signaling pathways that are involved in the 
control of MVEC barrier function, and that are often disrupted under pathological 
conditions, such as tissue injury or infection. 
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1.5 Metalloproteinases 
 Metalloproteinases are a diverse group of endopeptidases comprised of many 
distinct families [43]. Matrix metalloproteinases (MMPs) and the closely related a 
disintegrin and metalloproteinases (ADAMs) share several common structural domains, 
including a signal peptide, the pro-peptide domain, and the catalytic domain [44]. The 
pro-peptide domain contains a cysteine residue that ligates the active site zinc (Zn2+) or 
Ca2+ and maintains the enzyme in an inactive conformation until this interaction is 
disrupted. MMPs are generally categorized by their domain structure [45,46]. In addition 
to the domains common to all MMPs and other metalloproteinases (i.e. signal peptide, 
pro-domain, and catalytic domain), specific subsets of MMPs contain unique domains. 
Many MMPs contain a hemopexin-like C-terminal region, which is connected to the 
catalytic region by a short flexible hinge and can mediate protein-protein interactions (i.e. 
binding to tissue inhibitor of metalloproteinases [TIMPs]). Additionally, the membrane 
type (MT)-MMPs contain a furin-recognition domain allowing for activation by the pro-
protein convertase furin, as well as a C-terminal transmembrane domain [46–48]. 
ADAMs also contain a furin cleavage site as well as a disintegrin-binding domain, which 
can interact with integrins and mediate cell-ECM interactions [44]. 
 Metalloproteinases are regulated in four ways – gene expression, 
compartmentalization, pro-enzyme activation, and enzyme inactivation [46]. 
Metalloproteinase expression can be mediated by many factors, such as growth factors 
(e.g. transforming growth factor [TGF] β and vascular endothelial growth factor 
[VEGF]), cytokines (e.g. IFNγ, IL1β, and IL6), cell-ECM signaling through integrins, 
and pathogen-associated molecular patterns (PAMPs) [44,49,50]. 
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 Studies have shown that metalloproteinases demonstrate considerable overlap in 
their substrate selectivity in vitro. Thus, regulation of metalloproteinase activity is critical 
and likely occurs at multiple levels. Compartmentalization (e.g. the pericellular 
accumulation of metalloproteinases in specific microenvironments through cell-enzyme 
interactions) is thought to be important in regulating extracellular substrate degradation 
[44,46,50]. Additionally, while many metalloproteinases are secreted in their active form, 
some (i.e. specific MMPs) are secreted as zymogens, or inactive precursors, and remain 
in this inactive conformation due to the interaction between the pro-peptide and catalytic 
domains [47]. Disruption of this interaction, which occurs through multiple mechanisms 
including proteolytic removal or oxidation of the pro-domain, allows for MMP activity 
[46,47,49,51]. Finally, metalloproteinase activity is directly inhibited by specific 
inhibitors, the TIMPs [49,52].  
 Multiple MMPs are expressed by MVEC, some of which are localized to vesicles 
likely for rapid secretion following activation. While data on metalloproteinase regulated 
MVEC dysfunction is limited, changes in metalloproteinase expression in response to 
proinflammatory cytokines has been characterized in other types of EC. For example, 
angiotensin (ANG) II treatment of human umbilical vein endothelial cells (HUVEC) 
stimulates TNF production that leads to enhanced MMP2 production and release, and 
co-treatment with anti-TNF antibodies blocks this increased MMP2 production [53]. 
Interestingly, stimulation of brain EC with TNF and IL1, selectively upregulates 
MMP9 production, but does not alter MMP2 expression [54]. This suggests vascular bed 
specificity in MMP expression in response to cytokines. ADAM expression is also 
mediated by cytokines. Specifically, ADAM17 expression by murine brain EC is strongly 
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upregulated by many pro-inflammatory cytokines (i.e. TNF, IL-1, IFN) and growth 
factors (epithelial growth factor [EGF], VEGF) [55].  
 EC, including MVEC, also express and release higher levels of metalloproteinases 
following infection. For example, LPS, a component of the outer membrane of gram 
negative bacteria, elicits strong increases in the expression and activity of ADAM10 and 
ADAM17 in human PMVEC [56]. Further, Japanese encephalitis virus, a single stranded 
ribonucleic acid (RNA) virus, increases expression of MMP9 in human brain MVEC 
[57]. Additionally, infection of HUVEC with Chlamydophila pneumoniae, a bacteria 
associated with lung infections such as pneumonia, leads to increased MMP9 production 
while infection of HUVEC with Dengue virus leads to overproduction of MMP2 and to a 
lesser extent of MMP9 [57–59]. Finally, while it has yet to be linked to EC-specific 
expression, humans with severe sepsis have significantly elevated plasma MMP2, -3, -7, -
8, and -9 [60]. It is important to note, however, that at least part of the EC 
metalloproteinase response to infection may be mediated through autocrine signaling by 
cytokines expressed by EC in response to the infection.  
1.5.1 Role of Metalloproteinases in Endothelial Dysfunction 
 Multiple MMPs and ADAMs have been shown to cleave inter-MVEC junctional 
proteins, and thereby mediate microvascular dysfunction through increased vascular 
permeability [42,56,61–63]. For instance, MMP7, ADAM10, and -12 are all capable of 
cleaving VE-cadherin, the integral cell surface transmembrane protein of endothelial 
adherens junctions [42,62]. Further, increased MMP2 and -9 expression following 
HUVEC infection by Dengue virus is correlated with a loss of expression of VE-cadherin 
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cell-cell adhesion suggesting that MMP2 and -9 may also be capable of cleaving VE-
cadherin [59].  
 MMP2 and -9 along with ADAM17 are also capable of cleaving tight junction 
associated proteins such as occludin, zona occludens (ZO) 1, and junctional adhesion 
molecules (JAMs) [56,61,63]. In addition to cleavage, tyrosine phosphorylation-
dependent disassembly of crucial adhesive junctional proteins may also be MMP 
dependent, as permeability induced by tyrosine phosphatase inhibitors have been shown 
to be blocked by MMP inhibitors [41,64]. Moreover, knockdown of ADAM10 following 
small interfering RNA (siRNA) treatment of either EC or activated leukocytes stabilizes 
the microvascular barrier as well as reduces leukocyte transendothelial migration [42]. 
Collectively, these studies suggest increased metalloproteinase expression and activity 
promotes MVEC dysfunction through the cleavage and/or disruption of critical inter-
MVEC junctional proteins. 
 MMPs and ADAMs with thrombospondin motifs (ADAMTSs) have also been 
found to cleave the ECM surrounding the vasculature, which can modify EC function 
through disrupted endothelial-ECM interactions, ultimately leading to increased vascular 
permeability [65–70]. For example, proteolytic degradation of ECM constituents, 
including fibronectin, laminin, and type IV and V collagens, by MMPs, including MMP2 
and -9, results in increased permeability across EC monolayers in vitro as well as 
increased pulmonary edema in vivo [69,70]. The cleavage and degradation of other ECM 
protein constituents, including hyaluronan and aggrecan, have also been shown to 
augment endothelial permeability [70,71]. Additionally, MMP9 has been shown to be 
responsible for the cleavage and release of VEGF bound to the ECM, which results in 
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increased microvascular permeability through internalization of VE-cadherin [72]. Thus, 
these studies suggest increased metalloproteinase activity drives MVEC dysfunction 
through the proteolytic processing of integral MVEC structural determinants (i.e. the 
ECM) resulting in MVEC barrier dysfunction and enhanced microvascular leak. 
 Supportive evidence for the role of metalloproteinases in microvascular and MVEC 
dysfunction includes data from several studies using synthetic metalloproteinase 
inhibitors, such as GM6001. For example, stimulating HUVEC with TNF increases 
metalloproteinase expression and activity, and treatment of these HUVEC with GM6001 
reduces the TNF-induced increase in MVEC permeability through inhibition of VE-
cadherin cleavage [41,42]. Additionally, in models of brain edema due to dysfunction of 
the blood-brain barrier, treatment of murine cerebrovascular EC with GM6001 leads to 
decreased microvascular leak due to the stabilization of tight junction adhesive proteins 
and decreased EC F-actin stress fiber formation through the inhibition of MMP9 [73,74]. 
Collectively, these studies highlight the potential role of metalloproteinase inhibition in 
the control of MVEC barrier dysfunction. 
 In addition to controlling MVEC barrier dysfunction, metalloproteinases are also 
involved in mediating PMN-MVEC interaction through multiple potential mechanisms. 
Specifically, metalloproteinases, including both MMPs and ADAMs, can mediate PMN-
MVEC interaction through shedding of leukocyte receptors, such as intercellular 
adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), from the 
MVEC surface. For example, MMP14, as well as ADAM10 and -17 have been found to 
cleave ICAM1 [75–77]. Further, the interaction between ICAM1 and MMP14 appears to 
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be mediated by interaction between the cytoplasmic domains [77]. Additionally, 
ADAM17 has been shown to cleave VCAM1 from the surface of heart and aorta EC 
following stimulation with phorbol 12-myristate 13-acetate (PMA) [78]. Cleavage of 
ICAM1 and VCAM1 by MMPs and ADAMs reduces MVEC surface expression of 
ICAM1 and VCAM1 leading to decreased PMN-MVEC interaction [78]. These studies 
suggest that MMPs and ADAMs have the ability to downregulate PMN-MVEC 
interactions, reduce inflammation, and could also be involved in the resolution of 
inflammation. 
 Metalloproteinases have also been proposed to have a role in regulation of PMN-
MVEC interaction through cleavage of the glycocalyx. While degradation of the 
glycocalyx is thought to be primarily mediated by heparanase, glycocalyx degradation 
still occurs in mice lacking heparanase, and this degradation is associated with increased 
MMP activity [16,37]. Collectively, this potential degradation of the glycocalyx could 
lead to increased PMN-MVEC interaction; however, this remains to be confirmed. Thus, 
the role of metalloproteinases, including both MMPs and ADAMs, in MVEC dysfunction 
is complex, including promoting the loss of MVEC barrier function and increased 
leukocyte recruitment through degradation of the glycocalyx, while also decreasing direct 
leukocyte-MVEC interaction. Further, the specific roles likely depend on the 
metalloproteinase in question, the specific vascular bed, and the type of inflammation or 
injury.  
1.6 Tissue Inhibitor of Metalloproteinases (TIMPs) 
 The TIMP family is comprised of four members, TIMP1-4, in humans and other 
mammals (e.g. mice, rats) [52,79]. TIMPs inhibit active metalloproteinases in a 1:1 
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stoichiometric inhibitor-to-enzyme ratio [52,79]. Specifically, the N-terminal domain of 
TIMP molecules interacts with the active site of metalloproteinases in a fashion similar to 
metalloproteinase substrates, resulting in inhibition of catalytic activity [52,79].  
 TIMP expression varies in the different vascular beds throughout the body, 
including both micro- and macrovascular beds; however, all TIMP family members are 
expressed within at least one vascular bed, supporting the importance of TIMPs to EC 
function. For example, TIMP1, -3, and -4 are expressed by brain MVEC, and TIMP1, -2, 
and -3 are expressed by EC isolated from the aorta, iliac artery, and coronary artery [80–
82]. Additionally, TIMP3 is expressed by pulmonary MVEC, whereas TIMP2 and -4 do 
not appear to be [83,84].  
 Besides EC, TIMPs are also often expressed by multiple other cells associated with 
the vasculature. For example, TIMP3 is expressed by pericytes, and TIMP2 and -4 are 
expressed by vascular smooth muscle cells [85–87]. Importantly, TIMPs expressed by 
these adjacent cell populations are localized within the microenvironment surrounding 
the MVEC, and in many instances, have been found to be involved in regulation of 
MVEC function [85–88]. Additionally, while TIMP1, -2, and -4 are secreted and thus 
function in a soluble manner, TIMP3 is known to be bound to sulfated GAGs located in 
the ECM [52,79,89].  
 Within the setting of tissue injury and infection, the expression of the various 
TIMPs appears to be differentially regulated (i.e. expression of different TIMPs does not 
change in the same direction) [53,80,81,83,87,88,90,91]. For example, treatment of brain 
MVEC with pro-inflammatory cytokines, specifically IL1β and TNFα, led to an increase 
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in Timp1 and a decrease in Timp3 messenger ribonucleic acid (mRNA) expression [80]. 
Additionally, stimulation of brain MVEC with homocysteine, which is associated with 
endothelial dysfunction, increased TIMP1 expression but decreased TIMP4 expression 
[81]. 
 Interestingly, the TIMP expression in response to various stimuli also appears to be 
cell-dependent as stimulation of a transformed brain EC line (hCMEC/D3) with TNFα 
resulted in increased TIMP3 expression [92]. There is, however, some evidence 
suggesting that similar expression patterns for TIMPs may also be observed across 
different vascular beds. For example, while it has yet to be linked to MVEC-specific 
expression, TIMP1, -2, and -4 levels in plasma are significantly elevated in patients with 
severe sepsis [60,93,94]. Further, brain MVEC treated with homocysteine have increased 
TIMP1 protein expression [81]. Conversely, similar to the reduction in Timp3 expression 
in brain MVEC under inflammatory conditions, TIMP3 expression (mRNA and protein) 
was significantly decreased in pulmonary MVEC following treatment with IFN, IL1β, 
and TNFα [83]. 
1.6.1 Metalloproteinase-Dependent TIMP Functions 
 In general, all four TIMPs have been shown to collectively inhibit all MMPs in 
vitro [95,96]. There are, however, some differences between TIMPs. For example, 
TIMP1 does not appear to be able to regulate MT-MMPs [47,50]. In addition, ADAMs 
and ADAMTSs appear to be primarily inhibited by TIMP3 [47]. Some TIMPs have also 
been found to form a complex between an active MMP and latent pro-MMP leading to 
activation of the latent MMP. This has been demonstrated extensively with TIMP2, 
which binds active MMP14 and latent MMP2, and facilitates MMP2 activation [96].  
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 The majority of our understanding of metalloproteinase and TIMP interactions 
arises from in vitro studies utilizing purified proteins [95]. Hence, much of this data 
reveals the potential for metalloproteinase-TIMP interaction but does not provide 
information as to physiological relevance. There have been a number of in vivo studies 
using mice lacking specific TIMPs that have sought to identify physiological interactions. 
For example, TIMP1 has been found to interact with and inhibit MMP7 (also referred to 
as matrilysin) as MMP7 activity was increased in the airway epithelium of mice lacking 
TIMP1 following napthalene exposure [97]. Further, co-immunoprecipitation 
demonstrated that TIMP1 directly binds to MMP7 [97].  
 Use of different models of injury and inflammation with mice lacking TIMP3 have 
found that TIMP3 is the physiological inhibitor of ADAM17 [95]. Specifically, 
inflammation is generally increased in mice genetically lacking TIMP3 following 
multiple models of injury (i.e. partial hepatectomy, bleomycin-induced lung injury), and 
in most cases, this increased inflammation is associated with increased TNFα shedding 
resulting from augmented ADAM17 activity [98]. TIMP3 has also been associated with 
multiple other metalloproteinases in vivo, primarily through the observation of increased 
metalloproteinase activity (e.g. MMP9) or increased substrate degradation (e.g. aggrecan 
cleavage potentially by ADAMTS5) in mice lacking TIMP3 [95,99].  
 Rescue of the basal and pathological phenotypes in mice lacking specific TIMPs 
with small molecule metalloproteinase inhibitors also provides further support for the 
metalloproteinase dependent roles for TIMPs in vivo [83,98–101]. Thus, through 
regulation of metalloproteinase activity, TIMPs are able to finely tune processing of a 
wide variety of extracellular substrates ranging from degradation of the ECM to cleavage 
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of cytokines and cytokine receptors from the cell surface, which suggests TIMPs are 
critical for the regulation of many cellular functions from cell-cell interaction to influx of 
leukocytes into injured tissues. 
1.6.2 Role of TIMPs in Endothelial Function 
 A number of studies have characterized TIMP expression within multiple EC types 
under various conditions; however, the direct evidence of a role for EC-derived TIMPs in 
endothelial function is more limited. Indirect evidence from mice globally deficient for 
individual TIMPs as well as from studies of recombinant TIMPs suggests that TIMPs 
play an integral role in the setting of inflammation, as well as potentially in the setting of 
endothelial dysfunction following tissue injury. For example, TIMP1-3 all appear to 
support the blood brain barrier (BBB) following injury, although the mechanism may 
differ between TIMPs. Mice lacking TIMP1 have increased ischemic injury and blood-
brain barrier disruption compared to wild type (WT) mice following focal cerebral 
ischemia and this is associated with increased MMP9 secretion and activity [94]. Further, 
increased expression of TIMP1 in brain EC treated with ANG (1-7) following hypoxia-
induced injury was responsible for restoration of tight junctions and reduced EC 
permeability [102].  
 TIMP3 appears to regulate EC barrier function through metalloproteinase-
dependent mechanisms. Timp3-/- mice have augmented leak of Evans blue (EB)-labeled 
albumin into their snout and kidneys at baseline, which is thought to be due to the 
absence of TIMP3 in pericytes, resulting in enhanced microvascular permeability due to 
increased global metalloproteinase activity [68]. Timp3-/- mice also have increased 
pulmonary EB-albumin leak at baseline, which is likely due to loss of PMVEC-derived 
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TIMP3 as PMVEC from Timp3-/- mice also exhibit impaired barrier function in vitro 
compared to PMVEC from WT mice [83]. Further, treatment of Timp3-/- PMVEC with 
global metalloproteinase inhibitor GM6001 appears to restore basal PMVEC barrier 
function [83]. Together, these studies suggest that TIMP3 may be an important 
homeostatic regulator of EC function in healthy tissue, such as establishing a selectively 
permeable barrier, and that this role for TIMP3 is at least partly dependent on the ability 
of TIMP3 to inhibit metalloproteinases [70,83].  
 While the classic function for TIMPs is inhibition of metalloproteinase activity, 
there are multiple lines of evidence suggesting that TIMPs may regulate EC function 
through metalloproteinase-independent mechanisms. Specifically, mice lacking TIMP2 
exhibit blood-brain barrier disruption compared to WT mice following focal cerebral 
ischemia; however, no changes were observed in MMP activity [94]. Additionally, 
injection of recombinant TIMP3 (rTIMP3) led to decreased vascular leak across the 
blood-brain barrier in a model of traumatic brain injury, but this effect was not mimicked 
by use of a synthetic metalloproteinase inhibitor [103].  
 TIMP2 and -3 have also been found to inhibit VEGF signaling through 
metalloproteinase-independent mechanisms [90,91,104]. For TIMP3, this inhibition 
occurs through TIMP3 binding to the VEGF receptor (VEGFR) and blocking VEGF-
VEGFR2 interaction, ultimately inhibiting angiogenesis [90,91]. During angiogenesis, 
VEGF acts as a potent mediator of increased endothelial permeability through 
phosphorylation and internalization of VE-cadherin and subsequent disassembly of cell-
cell adhesive contacts [13,90,91,105]. Importantly, both TIMP2 and -3 have been found 
to inhibit angiogenesis, including inhibition of both EC proliferation and migration, 
19 
 
through inhibition of VEGF signaling [90,91,106]. Thus, these studies together suggest 
that TIMP2 and -3 may promote brain EC barrier function through metalloproteinase-
independent mechanisms. 
 In addition to regulation of MVEC barrier function, TIMPs have also been 
associated with regulation of PMN-MVEC interaction. Specifically, TIMP3 has been 
found to inhibit shedding of VCAM1 from the surface of aortic EC following treatment 
with IL1β, TNFα, or the phorbol ester PMA [106]. Specifically, aortic EC from Timp3-/- 
mice had increased VCAM1 shedding compared to aortic EC from WT mice, and this 
inhibition of VCAM1 shedding by TIMP3 was likely through inhibition of ADAM17 as 
knockdown of ADAM17 protected against increased VCAM1 shedding [106]. Thus, 
TIMPs appear to be critical regulators of MVEC dysfunction following tissue 
injury/infection, including protection against loss of MVEC barrier function through 
metalloproteinase-dependent and -independent mechanisms, as well as the regulation of 
leukocyte recruitment by stabilization of leukocyte receptors on the MVEC surface. 
1.7 Rationale 
Pathophysiological changes in the microvasculature are important mechanisms of 
sepsis-induced organ dysfunction and mortality. Specifically, increased pulmonary 
microvascular permeability during sepsis-induced ARDS, which is due to PMVEC 
injury, dysfunction and death, is the primary cause of the protein-rich edema fluid that 
accumulates within the damaged lung tissue [13,14,20–22,29,104]. While many 
mechanisms contributing to septic PMVEC injury/dysfunction have been described 
[13,14,20–22,28,29,104,107], no treatment for the septic tissue damage and organ 
dysfunction has been identified. Moreover, endogenous mechanisms protecting against 
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sepsis-induced PMVEC dysfunction are poorly characterized. Metalloproteinases are 
capable of processing many extracellular proteins, including inter-MVEC junctional 
proteins (i.e. VE-cadherin, JAM-A), and thereby disrupting MVEC barrier function and 
increasing microvascular permeability (Figure 1-1). TIMPs inhibit metalloproteinase 
activity, and thereby are critical to maintaining MVEC barrier function and restricting 
PMN-MVEC interaction. While recent studies support a role for metalloproteinases and 
TIMPs in mediating MVEC barrier dysfunction, many of these studies used in vitro 
models with HUVEC. Importantly, EC from the micro- and macrovasculature have 
different biological properties and thus, examining the role of metalloproteinases and 
TIMPs in the microvasculature, specifically in PMVEC, is critical [108,109]. Further, the 
potential role of the balance between metalloproteinases and TIMPs in regulating 
PMVEC barrier dysfunction as well as other aspects of PMVEC activation (i.e. leukocyte 
interactions) have not been examined under septic conditions. 
1.8 Objectives 
I propose to: 
1. Characterize PMVEC expression of metalloproteinases and TIMPs under 
control and septic conditions in vitro and ex vivo. 
2. Examine the role of the metalloproteinase/TIMP balance in PMVEC 
activation and dysfunction during sepsis in vitro. 
For this, I will examine PMVEC metalloproteinase and TIMP expression in WT 
PMVEC under homeostatic and septic conditions, as well as under conditions in which 
the metalloproteinase/TIMP balance has been disrupted (i.e. Timp3-/- PMVEC). To 
examine the role of the metalloproteinase/TIMP balance in PMVEC activation and  
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Figure 1-1: Disruption in the balance between metalloproteinases and tissue 
inhibitors of metalloproteinases (TIMPs) leading to increased metalloproteinase 
activity promotes microvascular endothelial cell (MVEC) activation and dysfunction 
following tissue injury or infection. (A) Cleavage of inter-MVEC junctional proteins 
(i.e. vascular endothelial [VE]-cadherin, junctional adhesion molecule [JAM]-A reduces 
MVEC barrier function and increases permeability for larger macromolecules. (B) 
Shedding of leukocyte receptors reduces polymorphonuclear leukocyte (PMN) adhesion 
to endothelial cells in an attempt to reduce increased PMN migration into the surrounding 
tissue. (C) Cleavage of the extracellular matrix/glycocalyx increases MVEC permeability 
and promotes PMN-MVEC interaction. Importantly, TIMPs inhibit metalloproteinase 
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activity, and thereby are critical to maintaining MVEC barrier function and restricting 
PMN-MVEC interaction.  
23 
 
dysfunction, I will utilize two complementary approaches: 1) PMVEC treated with 
synthetic metalloproteinase inhibitors, and 2) PMVEC from Timp3-/- mice. 
1.9 Hypothesis 
I hypothesize that septic murine PMVEC barrier dysfunction contributes to 
disruption of the balance between metalloproteinases and TIMPs leading to increased 
metalloproteinase activity. 
24 
 
Chapter 2  
2 Methodology 
2.1 Pulmonary Microvascular Endothelial Cell (PMVEC) 
Isolation for in vitro Analysis 
To study the function of the metalloproteinase/TIMP balance in maintaining 
pulmonary microvascular barrier function following septic lung injury, murine PMVEC 
were isolated from the lungs of healthy male WT and Timp3-/- mice and cultured for use 
in all in vitro experiments, as previously described [110,111]. In brief, following lung 
isolation, lung tissue was finely minced and digested using 0.3% collagenase in Hank’s 
Balanced Salt Solution (HBSS, #14170-112, Invitrogen). Following filtration through a 
100 μm pore mesh sieve, cells were incubated with magnetic microbeads (Dynabeads M-
450 sheep anti-rat IgG, #11035, Dynal Biotech Inc., Lake Success, NY), coupled to anti-
platelet endothelial cell adhesion molecule (PECAM; CD31) antibodies (Rat anti-mouse 
CD31 monoclonal antibody, #557355, BD Pharmingen, Franklin Lakes, NJ). Microbead-
bound PMVEC were magnetically captured (MPC magnet, Dynal Biotech Inc., Lake 
Success, NY) and subsequently washed and suspended in growth medium (Dulbecco’s 
modified Eagle’s medium [DMEM] supplemented with 20% heat inactivated fetal bovine 
serum [FBS], #11885-092, Invitrogen, Carlsbad, CA; 1% Penicillin/Streptomycin [10 
000 U/mL], #15140122, Invitrogen; 2% [4-2[2-hydroxyetyl]-1-piperazineethanesulfonic 
acid] [HEPES] buffer [1M], #15630-080, Invitrogen), then seeded into a 1% gelatin-
coated cell culture flask and incubated at 37°C with 5% carbon dioxide (CO2). Cells were 
assessed weekly to ensure appropriate morphology and once approximately 90% 
confluent, cells were stained with fluorescent acetylated-low density lipoprotein (LDL) 
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(Biomedical Technologies, # BT902, Stoughton, MA) and assessed by 
immunofluorescence, as well as stained with fluorescently-labelled antibodies against 
endothelial cell markers (i.e. CD31, CD34, CD146 and CD202) and assessed by flow 
cytometry to ensure purity. Collectively, these processes result in 99% PMVEC culture 
homogeneity. PMVEC were then grown in supplemented DMEM growth medium and 
incubated at 37°C with 5% CO2 until the cell monolayer reached confluence. PMVEC at 
passages 5-12 were used for all experiments 
2.2 PMVEC Isolation from Healthy and Septic Mice for ex 
vivo Analysis 
To further examine the role of the metalloproteinase/TIMP balance in sepsis, 
PMVEC were isolated from healthy (naïve and sham surgery) and septic (cecal ligation 
and perforation [CLP] model of sepsis) mice. For these studies, male WT and Timp3-/- 
mice (8-12 weeks) were randomized to control (naïve and sham surgery) or volume-
resuscitated CLP-sepsis for 1, 2, or 4h, as previously described [8,83]. Importantly, naïve 
mice exhibited no difference in gene expression compared to 4h sham mice, and thus 
were used in subsequent studies (Figure 2-1). PMVEC were isolated using the Mouse 
Lung Dissociation Kit (#130-095-927, Miltenyi) as per the manufacturer instructions. 
Briefly, the pulmonary vasculature was flushed with 10 mL saline and the lungs isolated. 
Lungs were then physically disrupted using the gentleMACSTM Dissociator (Miltenyi) 
followed by chemical digestion via Collagenase D and DNAse A (#130-095-927, 
Miltenyi) for 30 min at 37°C. The whole lung disgest was strained through 100 μm and 
70 µm cell strainers (#10199-658, VWR; #130-098-462, Miltenyi; respectively) and  
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Figure 2-1: Pulmonary MVEC (PMVEC) from sham mice exhibit no significant 
differences in gene expression compared to PMVEC from naïve mice. Timp and 
metalloproteinase mRNA expression are nearly identical, justifying the decision to use 
naïve mice instead of 4h sham mice for subsequent PMVEC endothelial cell isolation 
(n=4-8). 
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resuspended in DMEM supplemented with 0.5% bovine serum albumin (BSA) and 0.5M 
EDTA (pH 8.0). Once isolated, the whole lung cell suspension was incubated with CD45 
mouse MicroBeads (#130-097-153, Miltenyi) for 15 min at 4°C and then CD45+ cells 
were magnetically separated using LS columns (#130-042-401, Miltenyi). The CD45- 
cells were then incubated with CD31 mouse MicroBeads (#130-097-418, Miltenyi) for 15 
min at 4°C and the CD45-/CD31+ cells magnetically isolated using new LS columns. 
These cells were spun at 300 g for 5 min at 4°C, resuspended in phosphate buffered 
saline (PBS) with RNAse inhibitor (4U/ul, #129916, Qiagen), and placed at -80°C for 
storage. As above, purity of the isolated CD45-/CD31+ cells was confirmed by flow 
cytometry using fluorescently-labelled antibodies against endothelial cell markers (i.e. 
CD31, CD34, CD146 and CD202; Figure 2-2). 
2.3 Assessment of PMVEC Expression of Timp1-4, 
Metalloproteinases and Cell Adhesion Molecule 
Messenger Ribonucleic Acid (mRNA) 
PMVEC Timp1, -2, -3, -4, Mmp2, -7, -9, Adam10, -17, Icam1, Vcam1, and E-
selectin (Sele) mRNA expression levels were examined in male WT and Timp3-/- 
PMVEC in vitro, and in male WT and Timp3-/- PMVEC ex vivo by quantitative real-time 
polymerase chain reaction (qRT-PCR). For in vitro analysis, cells were cultured in 6-well 
cell culture plates coated with 1% gelatin. Once confluent, PMVEC were treated for 1, 2, 
and 4h with PBS (vehicle control), cytomix (an equimolar solution of TNFα, IL1β, and 
IFNγ, 30 ng/mL, PeproTech, Rocky Hill, NJ), LPS (10 μg/mL, 0111:B4 serotype, 
#L2630, Sigma) or a combination of both cytomix and LPS (30 ng/mL, 10 μg/mL, 
respectively), used to mimic septic conditions. Following stimulation, cells were lysed 
and RNA isolated using the RNeasy Mini Kit following the manufactures directions  
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Figure 2-2: CD45 and CD31 MicroBeads assist in selecting for a pure endothelial 
cell population. Compared to whole lung single cell suspension, CD31+-selected 
endothelial cells represent a purer population of endothelial cells, illustrated by the shift 
in fluorescence of CD31, CD34, CD146 and CD202 staining. CD45+-depleted/CD31+-
selected endothelial cells represent an even purer population, compared to both whole 
lung single cell suspension and CD31+-selected endothelial cells.  
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(#74104, Qiagen, Hilden, Germany). Briefly, 200 μL RLT buffer containing 2 μL beta- 
mercaptoethanol was added to each well. Wells were then scraped, and cell lysate 
collected and placed in Qiashredder tubes (#79656, Qiagen). Samples were spun at 14 
000 x g for 2 min. Flow through was collected from the Qiashredder tubes, placed into 
RNeasy spin columns, washed with a series of buffers, and the RNA eluted from the 
columns by water.  
For ex vivo analysis, RNA was isolated using the RNeasy Micro Kit (#74004, 
Qiagen, Hilden, Germany) from PMVEC isolated from naïve, sham, and septic mice as 
described in section 2.2. Briefly, cells were spun at 14 000 x g for 2 minutes and 
subsequently run through a genomic column for 1 minute at 10 000 x g.  
Flow through was collected and washed, and the RNA eluted from the columns. 
For all isolated RNA, purity (260/230 and 260/280 ratios) and concentration was 
determined by analysis with the NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Waltham, MA). Isolated RNA (2 μg) was reverse transcribed using a high capacity 
cDNA reverse transcription kit (#4368814, Invitrogen, Carlsbad, CA) according to 
manufacturer’s instructions.  
Gene expression was assessed using TaqMan Gene Expression Assays from 
Applied Biosystems (Timp1: Mm00441818_m1; Timp2: Mm00441825_m1; Timp3: 
Mm00441826_m1; Timp4: Mm01184417_m1; Mmp2: Mm00439498_m1; Mmp7: 
Mm00487724_m1; Mmp9: Mm00442991_m1; Adam10: Mm00545742_m1; Adam17: 
Mm00456428_m1; Icam1: Mm00516023_m1; Vcam1: Mm01320970_m1; Sele: 
Mm01310197_m1, Invitrogen) and the CFX96 Real Time System (BioRad Laboratories 
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Inc., Hercules, CA). Hypoxanthine-guanine phosphoribosyltransferase (Hprt), a 
housekeeping gene, was used to normalize expression of genes of interest 
(Mm00446968_m1, Invitrogen). qRT-PCR generated the cycle threshold (Ct) value for 
each gene and this value was then used to determine gene expression relative to control 
PMVEC (PBS-treated or isolated from naïve/sham mice). ΔCt was the normalization of 
the gene of interest (i.e. Timp3) to the housekeeping gene (Hprt) within a specific sample 
(i.e. 2h cytomix-treated PMVEC). ΔΔCt was the normalization of a specific sample (i.e. 
2h cytomix-treated PMVEC) to the control sample (PBS-treated PMVEC). Finally, the 
relative quantity (RQ) was the fold change in expression of a specific sample (i.e. 2h 
cytomix-treated PMVEC) relative to the control sample (PBS-treated PMVEC). RQ was 
determined by the following equation: RQ = 2-ΔΔCt. 
2.4 Assessment of PMVEC Metalloproteinase Activity 
Male WT and Timp3-/- PMVEC were grown to confluence in 6-well cell culture 
plates coated with 1% gelatin, and treated for 4h with PBS (vehicle control), cytomix (30 
ng/mL), LPS (10 μg/mL), or a combination of both cytomix and LPS (30 ng/mL and 10 
μg/mL, respectively). Following stimulation, the conditioned media was collected and 
placed at -80°C for storage. Cells were rinsed with PBS and then lysed by directly adding 
lysis buffer (1X CellLytic extraction buffer [#C2978-50ML, Sigma-Aldrich] into each of 
the wells. Cells were then placed on ice for 20 min, after which, the cell lysate was 
collected using cell scrapers and placed at -80°C storage.  
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2.4.1 Assessment of Global Metalloproteinase Activity 
Global metalloproteinase activity in the conditioned media and cell lysate was 
analyzed using the P126 OmniMMP fluorogenic substrate as per the manufacturer 
instructions (BML-P126-0001, Enzo Life Sciences). Briefly, 85 μL of conditioned media 
or 25 μL of cell lysate from each sample was added to each well of a clear bottom 96-
well black microplate (#82050-754, VWR). Fluorescently-labelled P126 substrate and 
assay buffer were then added to each well, including positive controls. Wells containing 
the reference peptide, P127 (BML-P127-0001, Enzo Life Sciences), were used as positive 
controls and wells containing sample and assay buffer but no P126 substrate were used as 
negative controls for background fluorescence. Additionally, to confirm that any 
observed increase in fluorescence was due to metalloproteinase activity, GM6001 and 
BB94 were added to a subset of wells. Fluorescence was measured (Excitation peak 
wavelength: 328 nm [320-340 nm]; Emission peak wavelength: 393 nm [393-405 nm]) 
using a Victor3 multilabel fluorescence microplate reader (Wallac) at 0, 3, 5, 7, 10, 20, 
and 30 min, and 1, 2, 3, 4, 5, 21 and 24h. The plate was incubated at 37°C with 5% CO2 
between readings. 
2.4.2 Assessment of A Disintegrin and Metalloproteinase (ADAM) 
17 Specific Activity 
ADAM17 activity was assessed in the cell lysate using the Sensolyte 520 Adam17 
Activity Assay Kit as per the manufacturer instructions (#AS-72085, AnaSpec). Briefly, 
25 μL of cell lysate from each sample was added to each well of a clear bottom 96-well 
black microplate (VWR). Fluorescently-labelled substrate and assay buffer were added to 
each sample, along with positive and negative controls. Wells containing purified 
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ADAM17 peptide were used as positive controls and wells containing the substrate and 
assay buffer but no sample were used as negative controls for background fluorescence. 
The fluorescence was measured (Excitation peak wavelength: 490 nm; Emission peak 
wavelength: 520 nm) using a Victor3 multilabel fluorescence microplate reader (Wallac) 
every 5 min for 2.5h. The plate was incubated at 37°C with 5% CO2 between readings. 
2.5 Assessment of PMVEC Barrier Integrity 
Endothelial monolayer integrity was assessed in male murine WT PMVEC using 
an in vitro model of PMVEC barrier function. WT PMVEC were seeded at a cell density 
of 2.5x104 cells/insert on 1% gelatin-coated transwell cell-culture inserts (3.0 μM pore, # 
CA62406-169, VWR Scientific Inc., Radnor, PA). PMVEC were grown to confluence in 
supplemented DMEM growth medium (as described above) in 24-well cell-culture plates. 
Baseline permeability of the PMVEC monolayer was assessed every second day using 
transendothelial electrical resistance (TEER), which is the most sensitive measure of 
paracellular permeability (e.g. to charged ions), to identify the time point at which a 
stable monolayer formed. 
Once a stable monolayer formed, baseline PMVEC barrier permeability was 
comprehensively assessed using three complementary techniques: (i) TEER; (ii) 
fluorescein isothiocyanate (FITC)-labelled dextran flux, which reflects small molecule 
paracellular permeability; and (iii) EB-labelled albumin flux, which is a clinicially 
relevant marker of both paracellular and transcellular permeability to large molecules. In 
general, assessment of PMVEC permeability by all three complementary techniques was 
conducted at five days after initial cell culture. 
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2.5.1 Assessment of PMVEC Transendothelial Electrical 
Resistance (TEER) 
Intact endothelial barriers exhibit high levels of TEER, and decreased TEER is 
indicative of physiological changes in PMVEC barrier function leading to increased 
trans-PMVEC permeability. TEER was measured across PMVEC monolayers by placing 
individual cell-culture inserts into the Endohm chamber (World Precision Instruments, 
Sarasota, Florida) in order to measure the electrical resistance in Ohms (Ω) using the 
EVOM2 Endothelial Voltohmmeter (World Precision Instruments, Sarasota, Florida). 
TEER across empty individual inserts not containing cultured PMVEC was used as a 
control to account for background resistance from the cell-culture inserts and this value 
was subtracted from the TEER measurements obtained from cell-culture inserts 
containing PMVEC.  
2.5.2 Assessment of trans-PMVEC Macromolecular Flux 
To further characterize PMVEC barrier function, movement of both small 
(dextran; a small, 3 kDa sugar derivative) and large (albumin; a large, 67 kDa protein 
found within blood) macromolecules from the upper chamber into the lower of the two-
chamber transwell system was assessed. Both FITC-labelled dextran and EB-labelled 
albumin were added directly to the upper chamber of the transwell insert containing the 
PMVEC monolayer, while the same concentration of unlabelled albumin was added to 
the lower chamber to remove osmotic pressure. Following 1h, the transwell inserts were 
removed, and the conditioned media of the lower chamber was collected. In order to 
measure FITC-labelled dextran flux, the fluorescence of the conditioned medium was 
measured (Excitation peak wavelength: 488 nm; Emission peak wavelength: 525 nm) 
34 
 
using a Victor3 multilabel fluorescence microplate reader (Wallac). Background 
fluorescence was measured in dextran-free DMEM. To measure EB-labelled albumin 
flux, absorbance of the conditioned medium was measured (A620) by an iMark™ 
Microplate Reader (BioRad Laboratories Inc., Hercules, CA). Background absorbance 
was measured in EB-albumin-free media. 
2.6 Assessment of PMVEC Barrier Function following 
PMVEC Stimulation 
Previous work in my lab reported the effects of cytomix stimulation (30 ng/mL) 
on TEER and trans-PMVEC macromolecular leak in PMVEC monolayers cultured on 
transwell cell-culture inserts [83,112]. These studies demonstrated that maximal trans-
PMVEC EB-labelled albumin leak occurred 4h following stimulation with cytomix [83]. 
To assess the effects of global metalloproteinase inhibitors on PMVEC barrier 
dysfunction under septic conditions, male WT PMVEC were grown to confluence on 
cell-culture inserts as described above and permeability assessed by all three 
complementary techniques following a 4h stimulation with either PBS (vehicle control) 
or cytomix (30 ng/mL) in the presence of vehicle control (dimethyl sulfoxide [DMSO] or 
distilled water [dH2O]) or synthetic metalloproteinase inhibitor (GM6001 [10 – 100 μM, 
#CC1010, EMD Millipore, St. Charles, MO], BB-94 [1 – 100 μM, #196440-5MG, EMD 
Millipore], or TAPI-2 [10 – 100 μM, #579052-1MG, EMD Millipore]). 
2.7 Assessment of PMVEC Cell Surface Adhesion 
Molecules 
Levels of PMVEC surface ICAM1, VCAM1 and E-selectin were examined in 
WT and Timp3-/- PMVEC by flow cytometry using the Guava easyCyte HT Flow 
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Cytometer (EMD Millipore). PMVEC were grown to confluence in 6-well cell culture 
plates coated with 1% gelatin, and treated with PBS (vehicle control), cytomix (30 
ng/mL), LPS (10 μg/mL) or a combination of both cytomix and LPS (30 ng/mL, 10 
μg/mL, respectively) for 4h. Following stimulation, PMVEC were trypsinized with 
0.05% Gibco trypsin-EDTA (1x) (Thermo Fisher Scientific), for 10 min, placed into 
Falcon tubes and spun at 200 g x 5 min, washed with 0.02% BSA, and then resuspended 
in 100 µL of 0.02% BSA. Fluorescently-labelled antibodies against ICAM1 (0.5 mg/mL; 
#116111, BioLegend), VCAM1 (0.5 mg/mL;  #105711, BioLegend), and E-selectin (0.2 
mg/mL; #553751, BD Biosciences) were then added to each tube and the PMVEC placed 
on a rotator for 40 min to ensure adequate staining. Unstained and stained PMVEC were 
washed with PBS, resuspended in 250 µL of 0.02% BSA, transferred to a 96 well round-
bottomed plate and assessed by flow cytometry. 
The effect of metalloproteinase inhibition on cytomix-induced PMVEC surface 
protein expression levels was also assessed. For these studies, PMVEC were treated with 
GM6001, BB-94, or TAPI-2 (100 µM) as above, or appropriate vehicle control (DMSO 
or dH2O) for 16 hours prior to cytomix stimulation. 
2.8 Assessment of Polymorphonuclear Leukocyte (PMN)-
PMVEC Interaction 
To examine PMN-PMVEC adhesion, WT and Timp3-/- PMVEC were grown to 
confluence on 24-well cell culture plates coated with 1% gelatin and bone marrow PMN 
were isolated from WT mice. Briefly, bone marrow was collected from the bones of WT 
mice into eppendorf tubes and spun at 3000 x g for 1 min. PMN were then isolated by 
density gradient centrifugation using 62% Percoll (#P4937, Sigma-Aldrich). Red blood 
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cells (RBC) were subsequently lysed with RBC lysis buffer solution (#00-4333-57, 
eBioscience), and the isolated PMN stained with calcein-AM (#17783, Sigma-Aldrich) 
for 30 min at 37°C. PMVEC and PMN were then treated separately with either PBS 
(vehicle control) or cytomix (10 ng/mL) for 4h. Following stimulation, PMN were added 
to PMVEC at a ratio of 10:1. After 30 min, cells were washed 3x with PBS to remove 
non-adherent PMN, and the adherent PMN and PMVEC monolayers lysed using 0.05% 
trypsin-EDTA. Lysate was then transferred to a clear bottom 96-well black microplate 
(#82050-754, VWR) and fluorescence measured using a Victor3 multilabel fluorescence 
microplate reader (Excitation: 488 nm; Emission: 525 nm; Wallac). Percentage of total 
neutrophil adhesion was determined by using a standard curve of labelled PMN. 
Background fluorescence was determined using unlabeled PMVEC. 
2.9 Statistical Analysis 
Differences between groups were assessed by t-test or a One-Way ANOVA with 
a Bonferroni post-hoc test for one independent variable, or by a Two-Way ANOVA with 
a Bonferroni post-hoc test for two independent variables using GraphPad Prism 6.2. 
Significance threshold was set at α = 0.05. Outliers were assessed using the Grubbs’ test. 
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Chapter 3  
3 Results 
3.1 Timp and Metalloproteinase mRNA Expression in Wild 
Type (WT) PMVEC 
Previous studies demonstrated that septic PMVEC barrier dysfunction appeared to 
peak after 4h cytomix-stimulation in vitro and in vivo [8,83,112]. Further, TIMP3 
appeared to be required for normal PMVEC barrier function, as mice lacking TIMP3 had 
increased basal PMVEC permeability [83]. Thus, PMVEC expression of all Timps and 
key metalloproteinases was examined in PMVEC under basal conditions and 1, 2, and 4h 
following in vitro and in vivo models of sepsis by qRT-PCR. Analysis of Timp1-4 
expression found that Timp2 had the highest basal expression and Timp4 had the lowest 
expression (Table 3-1; NOTE: Ct values of 35+ were considered as very low expression 
and Ct values of 40+ were considered to be absent). Mmp2, Adam10 and Adam17 
appeared to be expressed at high levels whereas basal expression of Mmp9 was fairly 
low, and Mmp7 was not detected (Table 3-1). Basal expression levels of Timp1-4 and 
metalloproteinases in PMVEC isolated from naïve WT mice ex vivo were similar to WT 
PMVEC in vitro (Table 3-2). 
3.1.1 Timp mRNA Expression is Altered in WT PMVEC under 
Septic Conditions 
Septic models had varying effects on Timp mRNA expression, with Timp4 mRNA 
expression remaining undetectable under all septic conditions (Figure 3-1). PMVEC 
stimulated with cytomix had significantly increased Timp1 mRNA expression by 4h post- 
stimulation, but had no changes in Timp2 and -3 mRNA expression (Figure 3-1). 
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Table 3-1: Average Basal (Threshold Cycle) Ct values for TIMP/metalloproteinase 
messenger ribonucleic acid (mRNA) expression in isolated murine wild type (WT) 
pulmonary MVEC (PMVEC) in vitro (n=22). 
Timp1 Timp2 Timp3 Timp4 Hprt1 
28.4 24.7 25.2 36.7 25.6 
Mmp2 Mmp7 Mmp9 Adam10 Adam17 
28.7 40+ 36.1 25.6 27.1 
 
Table 3-2: Average Basal Ct values for Timp/metalloproteinase mRNA expression in 
isolated murine WT PMVEC isolated ex vivo (n=8). 
Timp1 Timp2 Timp3 Timp4 Hprt1 
38.2 31.7 29.7 38.2 31.4 
Mmp2 Mmp7 Mmp9 Adam10 Adam17 
34.3 40+ 36.5 31.6 31.7 
 
  
39 
 
 
Figure 3-1: Timp messenger ribonucleic acid (mRNA) expression is altered in wild 
type (WT) PMVEC in vitro and ex vivo under septic conditions. Cytomix-stimulated 
WT PMVEC had an increase in Timp1 expression over 4h vs. PBS control (data 
expressed as relative quantitiy [RQ] of WT PBS). Lipopolysaccharide (LPS)-stimulated 
WT PMVEC had an increase in Timp1 expression and a decrease in Timp3 expression 
over 4h vs. PBS control (data expressed as RQ of WT PBS). Cytomix + LPS-stimulated 
WT PMVEC had an increase in Timp1 and Timp3 expression over 4h vs. PBS control 
(data expressed as RQ of WT PBS control). PMVEC from cecal ligation and perforation 
(CLP)-septic WT mice had an increase in Timp1, Timp2, and Timp3 expression vs. 
PMVEC from naïve WT mice (data expressed as RQ of WT naïve). Timp4 was not 
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detected at sufficient levels in all conditions. * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and + 
p<0.05 vs. 2 h, One-Way ANOVA followed by a Bonferroni post-hoc test, n=5-8.  
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LPS-stimulation of PMVEC significantly increased Timp1 mRNA expression by 4h post-
stimulation, had no effect on Timp2 mRNA expression, but significantly reduced Timp3 
mRNA expression by 4h post-stimulation. The combination of cytomix and LPS resulted 
in significant increases in Timp1 and -3 mRNA expression as early as 2h post-stimulation 
and this increase continued at 4h; however, no effect was observed on Timp2 mRNA 
expression (Figure 3-1).  
PMVEC isolated from CLP-septic mice had significantly increased Timp1 and -3 
mRNA expression as early as 2h post-CLP vs. PMVEC isolated from naïve mice, and 
this increase remained significant at 4h post-CLP. Timp2 mRNA expression was 
significantly increased by 1h post-CLP, but recovered to basal levels by 2h post-CLP 
(Figure 3-1). Interestingly, in vitro the individual stimulations (i.e. cytomix or LPS 
alone) caused significant changes to a single TIMP; however, the combined stimulation 
of cytomix and LPS in vitro appeared to be more representative of what was observed in 
vivo (Figure 3-1). 
3.1.2 Metalloproteinase mRNA Expression is Altered in WT 
PMVEC under Septic Conditions 
Because Timp mRNA expression levels were significantly altered under septic 
conditions, I next examined metalloproteinase mRNA expression. Cytomix stimulation of 
PMVEC in vitro significantly increased Mmp9 and Adam17 mRNA expression by 4h 
post-stimulation. Mmp2 and Adam10 mRNA expression did not change (Figure 3-2). 
LPS-stimulated PMVEC had significantly increased Mmp9 and Adam17 mRNA 
expression by 4h post-stimulation and no effect on Mmp2 and Adam10 mRNA expression 
(Figure 3-2). The combination of cytomix and LPS significantly increased Mmp9 and 
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Figure 3-2: Metalloproteinase mRNA expression is altered in WT PMVEC in vitro 
and ex vivo under septic conditions. Cytomix-stimulated WT PMVEC had an increase 
in Mmp9 and Adam17 expression over 4h vs. PBS control (data expressed as RQ of WT 
PBS). LPS-stimulated WT PMVEC had an increase in Mmp9 and Adam17 expression 
over 4h vs. PBS control (data expressed as RQ of WT PBS). Cytomix + LPS-stimulated 
WT PMVEC had an increase in Mmp9 and Adam17 expression and a decrease in Adam10 
over 4h vs. PBS control (data expressed as RQ of WT PBS). PMVEC from CLP-septic 
WT mice displayed an increase in Mmp9 expression vs. PMVEC from naïve WT mice 
(data expressed as RQ of WT naïve). * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and + p<0.05 
vs. 2 h, One-Way ANOVA followed by a Bonferroni post-hoc test, n=5-8. 
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Adam17 mRNA expression by 4h post-stimulation, significantly decreased Adam10 
mRNA expression by 4h post-stimulation, and had no effect on Mmp2 mRNA expression 
(Figure 3-2).  
PMVEC isolated from CLP-septic mice had significantly increased Mmp9 mRNA 
expression by 2h post-CLP. Once again, Mmp2 and Adam10 mRNA expression did not 
change; however, Adam17 mRNA expression had a trend towards increased expression. 
Thus, while in vitro septic models led to significant changes in PMVEC-derived 
metalloproteinase expression, only Mmp9 was significantly altered in the in vivo model 
of sepsis (Figure 3-2).  
3.2 Metalloproteinase Protein Activity in WT PMVEC under 
Septic Conditions 
My expression data suggests that the balance between PMVEC-derived TIMPs 
and metalloproteinases is disrupted under septic conditions; however, these changes in 
expression may not be indicative of overall changes in metalloproteinase activity, and 
thus, altered degradation or cleavage of proteins critical to PMVEC barrier function and 
PMN-PMVEC interaction. Either or both septic stimulations and expression 
independently or collectively could affect metalloproteinase activity. To examine the 
impact of septic stimulation and the resulting altered TIMP/metalloproteinase balance on 
metalloproteinase activity, I assessed global metalloproteinase activity within PMVEC 
lysates and in PMVEC-conditioned media, as well as the activity of a specific 
metalloproteinase, ADAM17, within the cell lysate. 
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3.2.1 Global Metalloproteinase Activity in the Conditioned Media is 
not Altered under Septic Conditions 
Multiple metalloproteinases expressed by PMVEC, including MMP2 and -9, are 
considered soluble MMPs and as such, may be released from the cell into the surrounding 
microenvironment. To examine the activity of these soluble metalloproteinases, I 
assessed total metalloproteinase within the conditioned media from WT PMVEC under 
basal conditions and after 4h of septic (cytomix, LPS, or a combination of both) 
stimulation. Compared to PBS control, soluble metalloproteinase activity was not 
significantly altered under septic conditions. However following stimulation with 
cytomix or the combination of cytomix and LPS, there appeared to be a trend towards 
decreased metalloproteinase activity (Cytomix: 7%; Cytomix + LPS: 10%; Figure 3-3). 
3.2.2 Global Metalloproteinase Activity in PMVEC Lysate is not 
Altered under Septic Conditions 
While soluble metalloproteinases are detected in the conditioned media, many 
metalloproteinases, including ADAMs, are found on the cell membrane. Further, soluble 
metalloproteinases expressed by PMVEC but not yet secreted, or bound to the cell 
surface through interaction with cell surface receptors such as integrins, are also 
associated with the cellular compartment. Thus, I next investigated global 
metalloproteinase activity within the PMVEC lysate. Surprisingly, compared to PBS 
control, total metalloproteinase activity was not significantly altered under septic 
conditions; however, there was a trend towards increased activity following cytomix 
stimulation (9%; Figure 3-4). 
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Figure 3-3: PMVEC-derived soluble metalloproteinase activity is not altered under 
4h septic conditions. Left panel: Representative graph of metalloproteinase activity 
(indicated by increase in relative fluorescence over time) in the conditioned media of WT 
PMVEC under basal and septic conditions. Right panel: Area under the curve (AUC) 
analysis revealed that compared to PBS control, PMVEC stimulated under septic 
conditions for 4h had no significant change in soluble metalloproteinase activity. 
However, PMVEC stimulated with cytomix and the combination of cytomix and LPS 
appeared to have a trend towards decreased metalloproteinase activity (n=6). 
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Figure 3-4: Total metalloproteinase activity in WT PMVEC lysate is not altered 
under 4h septic conditions. Left panel: Representative graph of metalloproteinase 
activity (indicated by increase in relative fluorescence over time) in the lysate of WT 
PMVEC under basal and septic conditions. Right panel: AUC analysis revealed that 
compared to PBS control, the lysate from PMVEC stimulated under septic conditions for 
4 hours had no change in global metalloproteinase activity. However, PMVEC stimulated 
with cytomix appeared to have a trend towards increased metalloproteinase activity 
(n=4).  
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3.2.3 ADAM17 Activity is Increased in WT PMVEC under Septic 
Conditions 
As showed in 3.1.2, PMVEC expression of Adam17, a metalloproteinase known 
to be associated with the cell membrane, was significantly increased under septic 
conditions, which suggests that the observed trend towards an increase in total 
metalloproteinase activity in PMVEC lysate could be due to increased ADAM17 activity. 
Analysis of PMVEC lysate ADAM17 activity revealed that ADAM17 activity was 
significantly increased following the combined stimulation of cytomix and LPS 
compared to PBS control (Figure 3-5). Further, there also appeared to be a trend towards 
increased ADAM17 activity following both cytomix and LPS stimulation (Cytomix: 8%; 
LPS: 6%; Figure 3-5). 
3.3 Inhibition of Metalloproteinase Activity Reduces WT 
PMVEC Barrier Dysfunction under Septic Conditions 
Septic stimulation, including cytomix and LPS, is well known to promote 
PMVEC barrier dysfunction [8,83,108,110,113,114]. Further, this PMVEC barrier 
dysfunction appears to be associated with a shift in the expression of metalloproteinases 
and TIMPs from the basal expression patters, and is also associated with increased 
metalloproteinase activity, specifically, ADAM17. However, whether this increased 
metalloproteinase activity is responsible for the septic PMVEC barrier dysfunction is 
unknown. To address this, permeability across WT PMVEC was assessed in vitro under 
septic conditions in the presence or absence of three global metalloproteinase inhibitors, 
GM6001, BB-94 or TAPI-2. Specifically, WT PMVEC were stimulated with PBS 
(vehicle control) or cytomix (30 ng/mL) for 4h in the presence of increasing  
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Figure 3-5: A disintegrin and metalloproteinase (ADAM) 17 activity appears to be 
increased in WT PMVEC lysate under 4h septic conditions. Left panel: 
Representative graph of ADAM17 activity (indicated by increase in relative fluorescence 
over time) in the lysate of WT PMVEC under basal and septic conditions. Right panel: 
AUC analysis revealed that compared to PBS control, PMVEC stimulated with cytomix 
and LPS together for 4h had significantly increased ADAM17 activity. PMVEC 
stimulated with cytomix and LPS separately appeared to have a trend towards increased 
ADAM17 activity. * p<0.05 vs. PBS, One-Way ANOVA followed by a Bonferroni post-
hoc test, n=4. 
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concentrations of GM6001, BB-94 or TAPI-2 (1-100 uM) or their vehicle controls 
(DMSO or dH2O) and TEER, as well as FITC-labelled dextran and EB-labelled albumin 
flux across the PMVEC monolayers was measured. WT PMVEC stimulated with 
cytomix for 4h was associated with a significant increase in PMVEC permeability as 
measured by decreased TEER and increased dextran and albumin flux (Figure 3-6 and 
3-7). Interestingly, compared to vehicle control, increasing concentrations of GM6001, 
BB-94, and TAPI-2 had no effect on TEER (Figure 3-6). Further, compared to DMSO 
control, increasing concentrations of GM6001 also had no effect on albumin and dextran 
flux across WT PMVEC under septic conditions (Figure 3-7). However, BB-94 
significantly reduced albumin flux vs. DMSO control at a concentration of 10 μM, and 
this reduction persisted at higher concentrations (Figure 3-7). Further, treatment with 
BB-94 also appeared to reduce dextran flux with a significant reduction observed at 25 
µM (Figure 3-7). Compared to dH2O, increasing concentrations of TAPI-2 also led to 
significantly reduced albumin and dextran flux at 25 μM (Figure 3-7). 
3.4 Basal differences between WT vs. Timp3-/- PMVEC 
Basal studies have demonstrated that basal Timp3-/- PMVEC permeability, as 
measured by TEER and macromolecular flux, is significantly greater than WT PMVEC 
[83]. Further, treatment of Timp3-/- PMVEC with a synthetic metalloproteinase inhibitor, 
GM6001, partially restored this increased permeability suggesting that increase was at 
least partly dependent on metalloproteinase activity [83]. Thus, I next began to further 
characterize the impaired barrier function in Timp3-/- PMVEC assessing Timp and 
metalloproteinase mRNA expression as well as metalloproteinase activity Timp3-/- 
PMVEC vs. WT PMVEC under basal conditions. Analysis of Timp expression  
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Figure 3-6: Transendothelial electrical resistance (TEER) is not altered following 
treatment with global metalloproteinase inhibitors. Compared to vehicle control 
(DMSO or dH2O), treatment of WT PMVEC with increasing concentrations of GM6001, 
BB-94, and TAPI-2 had no effect on TEER under basal or septic (cytomix, 30 ng/mL) 
conditions. * p<0.05 vs. PBS, Two-Way ANOVA followed by a Bonferroni post-hoc 
test, n=4-10. 
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Figure 3-7: Septic macromolecular flux is reduced following treatment with specific 
global metalloproteinase inhibitors. Compared to vehicle control (DMSO), increasing 
concentrations of GM6001 has no effect on albumin or dextran flux across WT PMVEC 
under septic (cytomix, 30 ng/mL) conditions. However, increasing concentrations of BB-
94 and TAPI-2 significantly reduced both albumin and dextran flux across WT PMVEC 
under septic conditions vs. vehicle control (DMSO/dH2O). * p<0.05 vs. PBS, and # 
p<0.05 vs. 0 μM, Two-Way ANOVA followed by a Bonferroni post-hoc test, n=3-5. 
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found that Timp2 had the highest basal expression and Timp4 had the lowest expression 
(Table 3-3). Mmp2, Adam10 and Adam17 appeared to be expressed at high levels 
whereas basal expression of Mmp9 was fairly low, and Mmp7 was not detected (Table 3-
3). Timp and metalloproteinase basal expression were similar in PMVEC isolated from 
naïve Timp3-/- mice ex vivo (Table 3-4). 
3.4.1 Metalloproteinase and Timp mRNA Expression in Timp3-/- 
PMVEC is Similar to WT PMVEC under Basal Conditions 
Analysis of metalloproteinase and Timp mRNA expression in WT and Timp3-/- 
PMVEC in vitro under basal conditions revealed no significant differences between 
genotypes, except for Timp3, which is not present in Timp3-/- PMVEC (Figure 3-8). 
Similarly, in PMVEC isolated from naïve mice, compared to WT, Timp3-/- PMVEC had 
no significance differences in Timp or metalloproteinase expression, except for Timp3 
(Figure 3-9). 
3.4.2 Metalloproteinase Activity Appears Decreased in Timp3-/- vs. 
WT PMVEC under Basal Conditions 
Analysis of global metalloproteinase activity in conditioned media from WT and 
Timp3-/- PMVEC under basal conditions demonstrated significantly reduced 
metalloproteinase activity in the conditioned media from Timp3-/- PMVEC compared to 
WT PMVEC (15%; Figure 3-10A). Interestingly, no significant differences in global 
metalloproteinase activity or in ADAM17 activity were noted between genotypes in the 
cell lysate under basal conditions (Figure 3-10B and C). 
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Table 3-3: Average Basal Ct values for Timp/metalloproteinase mRNA expression in 
isolated murine Timp3-/- PMVEC in vitro (n=22). 
Timp1 Timp2 Timp3 Timp4 Hprt1 
28.4 25.0 -/- 36.4 25.5 
Mmp2 Mmp7 Mmp9 Adam10 Adam17 
28.5 40+ 36.0 26.0 27.1 
 
Table 3-4: Average Basal Ct values for Timp/metalloproteinase mRNA expression in 
isolated murine Timp3-/- PMVEC ex vivo (n=5). 
Timp1 Timp2 Timp3 Timp4 Hprt1 
37.2 30.2 -/- 38.2 31.4 
Mmp2 Mmp7 Mmp9 Adam10 Adam17 
33.0 40+ 35.4 30.0 30.5 
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Figure 3-8: Timp and metalloproteinase mRNA expression is not altered in Timp3-/- 
PMVEC vs. WT PMVEC at basal levels in vitro. No significant differences were 
observed in Timp or metalloproteinase expression, except for Timp3, in Timp3-/- PMVEC 
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vs. WT PMVEC. Data expressed as the RQ of WT control, * p<0.05 vs. WT, paired t-
test, n=22. 
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Figure 3-9: Timp and metalloproteinase mRNA expression is not altered in Timp3-/- 
PMVEC isolated from naïve mice. No significant differences in Timp or 
metalloproteinase expression, except Timp3, were found in Timp3-/- PMVEC vs. WT 
PMVEC isolated from naïve mice. Data expressed as the RQ of WT control, * p<0.05 vs. 
WT, paired t-test, n=5-8. 
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Figure 3-10: Metalloproteinase activity appears reduced in Timp3-/- PMVEC vs. WT 
PMVEC under basal conditions in vitro. Left panel: Representative graph of 
metalloproteinase activity (indicated by increase in relative fluorescence over time) in the 
conditioned media (A) and lysate (B, C) of WT and Timp3-/- PMVEC under basal 
conditions. Right panel: AUC analysis revealed that compared to WT, Timp3-/- PMVEC 
had (A) significantly reduced soluble metalloproteinase activity, (B) no change in global 
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metalloproteinase activity, (C) no change in ADAM17 activity. * p<0.05 vs. WT, paired 
t-test, n=4-6. 
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3.5 Timp and Metalloproteinase mRNA Expression in 
Timp3-/- PMVEC 
While no differences were observed in metalloproteinase and Timp expression 
between WT and Timp3-/- PMVEC under basal conditions, TIMP3 has been previously 
found to mediate pro-inflammatory signalling and as such, it is possible that the response 
of Timp3-/- PMVEC to septic stimuli could be altered [49,98,100,101,115]. To assess this, 
I next examined Timp and metalloproteinase expression data in Timp3-/- PMVEC under 
septic conditions. 
3.5.1 Timp mRNA Expression is Altered in Timp3-/- PMVEC under 
Septic Conditions 
PMVEC-derived expression of all Timps and key metalloproteinases was 
examined in Timp3-/- PMVEC at 1, 2, and 4h following in vitro (cytomix, LPS, and both 
cytomix and LPS) and in vivo (CLP) models of sepsis by qRT-PCR. Similar to WT 
PMVEC, in Timp3-/- PMVEC, Timp1 mRNA expression was significantly increased at 4h 
post-cytomix, as well as at 2 and 4h post-stimulation with both cytomix and LPS, while 
Timp2 mRNA expression was not altered under septic conditions in vitro (Figure 3-11). 
Further, Timp1 mRNA expression was significantly increased at 4h post-CLP in PMVEC 
from Timp3-/- mice (Figure 3-11). Additionally, in PMVEC from Timp3-/- mice, Timp2 
mRNA expression appeared to trend towards an increase at 1 and 2h post-CLP, but was 
significantly reduced at 4h post-CLP (Figure 3-11). 
3.5.2 Metalloproteinase mRNA Expression is Altered in Timp3-/- 
PMVEC under Septic Conditions 
I next examined metalloproteinase mRNA expression in Timp3-/- PMVEC under 
septic conditions in vitro and in vivo. Cytomix stimulation of PMVEC significantly  
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Figure 3-11: Timp mRNA expression is altered in Timp3-/- PMVEC in vitro and ex 
vivo under septic conditions. Cytomix-stimulated Timp3-/- PMVEC had an increase in 
Timp1 expression  over 4h vs. PBS control (data expressed as RQ of PBS). LPS-
stimulated Timp3-/- PMVEC had no significant changes in Timp expression over 4h vs. 
PBS control (data expressed as RQ of PBS). Cytomix + LPS-stimulated Timp3-/- PMVEC 
had an increase in Timp1 expression over 4h vs. PBS control (data expressed as RQ of 
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PBS). PMVEC isolated from CLP-septic Timp3-/- mice had an increase in Timp1 
expression over 4h and significantly decreased Timp2 expression at 4h vs. PMVEC from 
naïve Timp3-/- mice (data expressed as RQ of naïve). Timp3 and -4 were not detected at 
sufficient levels under any condition. * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and + p<0.05 
vs. 2 h, One-Way ANOVA followed by a Bonferroni post-hoc test, n=3-8. 
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increased Mmp9 and Adam17 mRNA expression by 4h post-stimulation. Mmp2 and 
Adam10 mRNA expression did not change (Figure 3-12). LPS-stimulated PMVEC had 
significantly increased Mmp9 by 2h post-stimulation, and this increase remained 
significant at 4h post-stimulation. Interestingly, Adam10 mRNA expression significantly 
reduced by 1h post-stimulation, and this decrease remained significant at 2 and 4h post-
stimulation. Mmp2 and Adam17 mRNA expression did not change; however, Adam17 
expression appeared to trend towards increased expression (Figure 3-12). Further, the 
combination of cytomix and LPS significantly increased Mmp2, -9, and Adam17 mRNA 
expression at 4h post-stimulation. Adam10 mRNA expression, however, remained 
constant at all time points (Figure 3-12). Finally, PMVEC isolated from CLP-septic 
Timp3-/- mice had significantly increased Mmp9 and Adam17 mRNA expression at 1 and 
2h post-CLP; however, expression of both returned to basal levels at 4h post-CLP. No 
significant differences in Mmp2 and Adam10 mRNA expression were observed in 
PMVEC isolated from CLP-septic Timp3-/- mice (Figure 3-12). 
3.6 Metalloproteinase Activity in Timp3-/- PMVEC under 
Septic Conditions 
Once again, my expression data suggests that the balance between PMVEC-
derived TIMPs and metalloproteinases is disrupted under septic conditions; however, 
these changes in expression may not be indicative of overall changes in metalloproteinase 
activity. To examine the impact of the altered TIMP/metalloproteinase balance on 
metalloproteinase activity, I assessed global metalloproteinase activity within the 
conditioned media and within the cell lysate, as well as the activity of a specific 
metalloproteinase, ADAM17, within the cell lysate under septic conditions.  
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Figure 3-12: Metalloproteinase mRNA expression is altered in Timp3-/- PMVEC in 
vitro and ex vivo under septic conditions. Cytomix-stimulated Timp3-/- PMVEC had an 
increase in Mmp9 and Adam17 expression over 4h vs. PBS control (data expressed as RQ 
of PBS). LPS-stimulated Timp3-/- PMVEC had an increase in Mmp9 expression and a 
decrease in Adam10 expression over 4h vs. PBS control (data expressed as RQ of PBS). 
Cytomix + LPS-stimulated Timp3-/- PMVEC had an increase in Mmp2, Mmp9 and 
Adam17 expression over 4h vs. PBS control (data expressed as RQ of PBS). PMVEC 
from CLP-septic Timp3-/- mice had an increase in Mmp9 and Adam17 expression over 4h 
vs. PMVEC from naïve Timp3-/- mice (data expressed as RQ of naïve). * p<0.05 vs. PBS, 
# p<0.05 vs. 1 h, and + p<0.05 vs. 2 h, One-Way ANOVA followed by a Bonferroni 
post-hoc test, n=3-8. 
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3.6.1 Global Metalloproteinase Activity in the Conditioned Media is 
not Altered under Septic Conditions in Timp3-/- PMVEC 
To examine the activity of soluble metalloproteinases, I assessed total 
metalloproteinase within the conditioned media from Timp3-/- PMVEC under basal 
conditions and after 4h of septic (cytomix, LPS, or a combination of both) stimulation. 
Compared to PBS control, soluble metalloproteinase activity was not significantly altered 
under septic conditions. However following stimulation, there appeared to be a trend 
towards decreased metalloproteinase activity (Cytomix: 6%; LPS: 11%; Cytomix + LPS: 
12%; Figure 3-13). 
3.6.2 Global Metalloproteinase Activity in Timp3-/- PMVEC Lysate 
is not Altered under Septic Conditions 
I investigated global metalloproteinase activity within the cell lysate, which 
contains many membrane bound metalloproteinases, as well as soluble 
metalloproteinases, which have not been secreted, or bound to the cell surface through 
interaction with cell surface receptors. Compared to PBS control, total metalloproteinase 
activity was not significantly altered under septic conditions. However, following 
cytomix stimulation and the combined stimulation of cytomix and LPS, there appeared to 
be a trend towards decreased and increased metalloproteinase activity, respecitvely 
(Cytomix: 10%; Cytomix + LPS: 23%; Figure 3-14). 
3.6.3 ADAM17 Activity is not Altered in Timp3-/- PMVEC under 
Septic Conditions 
Expression of Adam17, a metalloproteinase known to be associated with the cell 
membrane, was significantly increased under septic conditions, which suggests that the 
observed trend towards an increase in total metalloproteinase activity in the cell lysate  
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Figure 3-13: Timp3-/- PMVEC-derived soluble metalloproteinase activity is not 
altered under 4h septic conditions. Left panel: Representative graph of 
metalloproteinase activity (indicated by increase in relative fluorescence over time) in the 
conditioned media of Timp3-/- PMVEC under basal and septic conditions. Right panel: 
AUC analysis revealed that compared to PBS control, PMVEC stimulated under septic 
conditions for 4h had no significant change in soluble metalloproteinase activity. 
However, PMVEC under septic conditions appeared to have a trend towards decreased 
metalloproteinase activity (n=6). 
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Figure 3-14: Total metalloproteinase activity in Timp3-/- PMVEC lysate is not 
altered under 4h septic conditions. Left panel: Representative graph of 
metalloproteinase activity (indicated by increase in relative fluorescence over time) in the 
lysate of Timp3-/- PMVEC under basal and septic conditions. Right panel: AUC analysis 
revealed that compared to PBS control, the lysate from PMVEC stimulated under septic 
conditions for 4h had no change in global metalloproteinase activity. However, PMVEC 
under cytomix and cytomix + LPS stimulation appeared to have a trend towards 
decreased and increased metalloproteinase activity, respectively (n=4). 
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could be due to increased ADAM17 activity. PMVEC stimulated under septic conditions 
after 4h had no significant change in ADAM17 activity. However, PMVEC stimulated 
with LPS and the combination of cytomix and LPS appeared to have a trend towards 
increased activity (LPS: 23%; Cytomix + LPS: 52%; Figure 3-15). 
3.7 Endothelial Barrier Dysfunction is Associated with 
Increased Cell Surface Expression of PMVEC Cell 
Adhesion Molecules 
3.7.1 PMVEC Cell Adhesion Molecule mRNA Expression is 
Increased in WT and Timp3-/- PMVEC under Septic 
Conditions 
Expression of Icam1, Vcam1, and Sele mRNA levels was examined in WT and 
Timp3-/- PMVEC in vitro following stimulation with cytomix, LPS, or both for between 
1-4h. Cytomix stimulation of WT and Timp3-/- PMVEC significantly increased Icam1, 
Vcam1, and Sele (Figure 3-16). LPS stimulation of WT PMVEC significantly increased 
Sele mRNA expression, as well as Icam1, Vcam1, and Sele mRNA expression in Timp3-/- 
PMVEC (Figure 3-16). Icam1 and Vcam1 mRNA expression trended towards increased 
expression in LPS-stimulated WT PMVEC (Figure 3-16). Under each septic condition, 
Sele mRNA expression decreased at 2 and 4h in both WT and Timp3-/- PMVEC (Figure 
3-16). Cytomix and LPS stimulation of WT PMVEC led to a significant increase vs. PBS 
control in Icam1 and Vcam1 mRNA expression by 1h post-stimulation, which persisted at 
2h and continued to increase at 4h post-stimulation. Sele mRNA expression significantly 
increased by 1h post-stimulation, and remained significantly increased at 2 and 4h vs. 
PBS control; however, Sele expression was decreased at 2 and 4h post-stimulation vs. 1h 
post-stimulation (Figure 3-16). Timp3-/- PMVEC stimulated with both cytomix and LPS  
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Figure 3-15: ADAM17 activity is not altered in Timp3-/- PMVEC lysate under 4h 
septic conditions. Left panel: Representative graph of ADAM17 activity (indicated by 
increase in relative fluorescence over time) in the lysate of Timp3-/- PMVEC under basal 
and septic conditions. Right panel: AUC analysis revealed that compared to PBS control, 
PMVEC stimulated under septic conditions for 4h had no significant change in ADAM17 
activity. PMVEC stimulated with LPS and a combination of cytomix and LPS appeared 
to have a trend towards increased ADAM17 activity (n=4). 
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Figure 3-16: Septic models increase expression of PMVEC cell adhesion molecules 
in vitro. Icam1, Vcam1, and Sele mRNA expression is significantly increased following 
stimulation with cytomix, LPS, and cytomix + LPS over 4h time course in both WT and 
Timp3-/- PMVEC. When focused on cytomix + LPS stimulated PMVEC, the increased 
expression, however, appears to be of a greater magnitude in Timp3-/- PMVEC vs. WT 
PMVEC.  * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and + p<0.05 vs. 2 h, One-Way ANOVA 
followed by a Bonferroni post-hoc test, n=6-8. 
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revealed similar trends in Icam1, Vcam1, and Sele mRNA expression over the entire time 
course; however, compared to WT PMVEC, Timp3-/- PMVEC expression of cell 
adhesion molecules appeared to be 1.5-4 fold increased under septic conditions (Figure 
3-16). 
3.7.2 Cell Surface Expression of PMVEC Cell Adhesion Molecules 
is Increased in WT and Timp3-/- PMVEC under Septic 
Conditions 
Flow cytometry was used to examine the cell surface levels of ICAM1, VCAM1, 
and E-selectin on WT and Timp3-/- PMVEC under basal and septic conditions. For these 
studies, PMVEC were treated in vitro with PBS, cytomix, LPS, or a combination of both 
cytomix and LPS for 4h. Compared to PBS control, ICAM1, VCAM1, and E-selectin 
levels were increased under septic conditions in both WT and Timp3-/- PMVEC (Figure 
3-17). Analysis of the geometric mean fluorescence intensity (MFI) demonstrated that, in 
general, ICAM1, VCAM1, and E-selectin cell surface abundance increased significantly 
under septic conditions in both WT and Timp3-/- PMVEC (Figure 3-18). Specifically, 
ICAM1, VCAM1, and E-selectin MFI significantly increased in WT and Timp3-/- 
PMVEC following stimulation with cytomix and the combination of cytomix and LPS. 
ICAM1 and VCAM1 also significantly increased following LPS stimulation in WT 
PMVEC with a trend towards increased expression in Timp3-/- PMVEC. Interestingly, 
compared to WT PMVEC, ICAM1 cell surface levels were significantly reduced in 
Timp3-/- PMVEC under basal as well as each septic condition – this decreased abundance 
in the Timp3-/- vs. WT PMVEC was not seen for VCAM1 or E-selectin (Figure 3-18). 
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Figure 3-17: Cell adhesion molecule abundance appears increased on the cell 
surface of PMVEC under septic conditions in vitro. Representative flow cytometry 
histograms from WT and Timp3-/- PMVEC demonstrated that PMVEC stimulated with 
cytomix and LPS for 4h (dark grey histogram) had increased ICAM1, VCAM1 and E-
selectin vs. PBS control (tan histogram). Further, under basal and under septic conditions, 
ICAM appeared to be more abundant on WT vs. Timp3-/- PMVEC. Little background 
fluorescence was observed in unstained cells (white histogram; n=4-5). 
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Figure 3-18: Cell adhesion molecule abundance is significantly increased on the cell 
surface of PMVEC under septic conditions in vitro. Analysis of the mean fluorescence 
intensity (MFI) revealed that ICAM1, VCAM1 and E-selectin cell surface abundance is 
significantly increased in WT and Timp3-/- PMVEC under septic conditions. Further, 
under basal and septic conditions, ICAM cell surface abundance is significantly increased 
in WT vs. Timp3-/- PMVEC. # p<0.05 vs. PBS, # p<0.05 vs. WT, Two-Way ANOVA 
followed by a Bonferroni post-hoc test, n=4-5. 
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3.8 Cell Surface Intercellular Adhesion Molecule (ICAM) 1 
Deficiency in Timp3-/- PMVEC under Basal Conditions 
Appears Metalloproteinase Independent 
To begin to determine the mechanism through which TIMP3 regulates PMVEC 
surface ICAM1 expression under basal conditions, WT and Timp3-/- PMVEC were 
treated with global metalloproteinase inhibitors. Surprisingly, treatment with GM6001, 
BB94 or TAPI-2 had no effect on ICAM1 cell surface abundance on either WT or Timp3-
/- PMVEC compared to DMSO or dH2O control (Figure 3-19). Moreover, cell surface 
ICAM1 remained significantly decreased on Timp3-/- vs. WT PMVEC in all treatment 
groups (Figure 3-19 and 3-20). Additionally, no changes were observed in VCAM1 or E-
selectin cell surface abundance in any of the treatment groups (Figure 3-20). 
3.9 Timp-/- PMVEC have Decreased PMN Adhesion under 
Basal and Septic Conditions 
The decreased ICAM1 abundance on the surface of Timp3-/- PMVEC may 
interfere with PMN adhesion as ICAM1 is a critical receptor for CD11b on the leukocyte 
cell surface [116]. Thus, I next investigated the potential role of TIMP3 in regulating 
PMN-PMVEC adhesion. For these studies, WT and Timp3-/- PMVEC as well as WT 
PMN were stimulated separately with cytomix for 4h before being combined for 30 min 
to measure static adhesion. Under basal conditions, PMN adhesion to WT PMVEC was 
approximately 15% of PMN whereas adhesion to Timp3-/- PMVEC was approximately 
10% (Figure 3-21). Cytomix stimulation significantly increased PMN adhesion to both 
WT and Timp3-/- PMVEC (31% and 24%, respectively (Figure 3-21). However, under 
both basal and septic conditions, significantly fewer PMN adhered to Timp3-/- vs. WT 
PMVEC (Figure 3-21). 
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Figure 3-19: Global metalloproteinase inhibitors have no effect on PMVEC 
intercellular adhesion molecule (ICAM) 1 cell surface abundance in vitro. 
Representative flow cytometry histograms from WT and Timp3-/- PMVEC demonstrated 
that compared to vehicle control (DMSO and dH2O; tan histogram), treatment with 
GM6001, BB-94, and TAPI-2 (black histogram) had no effect on ICAM1 cell surface 
abundance on WT and Timp3-/- PMVEC under basal conditions (n=3). 
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Figure 3-20: Global metalloproteinase inhibitors have no effect on the cell surface 
abundance of cell adhesion molecules on PMVEC in vitro. Analysis of MFI revealed 
that compared to vehicle control (DMSO and dH2O), GM6001, BB-94, and TAPI-2 had 
no effect on ICAM1, VCAM1, or E-selectin cell surface abundance on WT and Timp3-/- 
PMVEC under basal conditions. Further, Timp3-/- PMVEC had significantly decreased 
cell surface ICAM1 abundance vs. WT PMVEC under all conditions. * p<0.05 vs. WT, 
Two-Way ANOVA followed by a Bonferroni post-hoc test, n=3. 
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Figure 3-21: Timp3-/- PMVEC have reduced polymorphonuclear leukocyte (PMN) 
adhesion. Compared to PBS, WT and Timp3-/- PMVEC have significantly increased 
PMN adhesion; however, Timp3-/- PMVEC have significantly reduced PMN adhesion 
under both basal and under septic (cytomix, 30 ng/mL) conditions compared to WT 
PMVEC. * p<0.05 vs. PBS and # p<0.05 vs. WT, Two-Way ANOVA followed by a 
Bonferroni post-hoc test, n=7. 
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Chapter 4  
4 Discussion 
4.1 Summary of Findings 
Sepsis is a common and serious condition characterized by life-threatening organ 
dysfunction caused by a dysregulated host response to infection [1]. Excessive 
inflammation causes pathophysiological changes, including increased microvascular 
permeability, leading to organ damage and dysfunction distant to the site of infection. In 
particular, the accumulation of alveolar protein-rich edema observed in sepsis-induced 
ARDS is thought to be caused by injury and dysfunction of PMVEC and the alveolar 
epithelium due to excessive inflammation, characterized by a loss of structural integrity 
and resulting barrier dysfunction [11,12]. PMVEC are critical in maintaining homeostatic 
microvascular function by monitoring vascular tone, and controlling both the migration 
of circulating cells and the movement of macromolecules across the intact microvascular 
barrier into the lung [14,20–23]. Many mechanisms of septic PMVEC injury and 
dysfunction have been described.  The endogenous mechanisms protecting against sepsis-
induced PMVEC dysfunction, however, are not well defined. 
Thus, I sought to investigate the metalloproteinase-dependent role of PMVEC-
derived TIMPs in the regulation of normal and septic murine microvascular barrier 
function. My data suggest that the balance between TIMPs and metalloproteinases is 
disrupted under septic conditions, leading to increased metalloproteinase activity and 
PMVEC barrier dysfunction. Furthermore, disruption of this balance (loss of TIMP3) is 
associated with impaired PMN recruitment. Therefore, this study demonstrates that 
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TIMPs may mediate a novel, endogenous mechanism that promotes PMVEC barrier 
function under healthy conditions, and that this homeostatic mechanism may be disrupted 
under septic conditions. 
4.2 Contributions of Research to Current State of 
Knowledge 
4.2.1 TIMP/Metalloproteinase Levels in Septic PMVEC 
Previous studies have demonstrated that stimulation of murine WT PMVEC 
monolayers in vitro with cytomix at a concentration of 30 ng/mL led to significant barrier 
dysfunction, as measured by decreased TEER and enhanced trans-PMVEC EB-labelled 
albumin and FITC-labelled dextran flux, by 4h post-stimulation [83]. Thus, Timp and 
metalloproteinase mRNA expression levels were examined in WT and Timp3-/- PMVEC, 
over the same timeline in order to assess the role of TIMPs in sepsis-induced PMVEC 
dysfunction. The assessment of Timp mRNA expression following cytomix, LPS (10 
μg/mL), or a combination of both revealed septic WT PMVEC express significantly 
higher Timp1 mRNA levels than PBS-treated WT PMVEC.  Significant alterations in 
Timp3 mRNA expression levels, which depended on the septic stimuli, were also 
observed compared to PBS-treated WT PMVEC. Further, Timp2 mRNA expression did 
not change under various septic conditions, and Timp4 mRNA expression was not 
detected in WT PMVEC.  
Overall, my data demonstrates the importance of TIMPs in pulmonary 
microvasculature, with TIMP1, -2, and -3 all being expressed under basal conditions. 
TIMP expression varies in the different vascular beds throughout the body, including 
both micro- and macrovascular beds; however, all TIMP family members are expressed 
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within at least one vascular bed supporting the broad importance of TIMPs in EC 
function. For example, TIMP1, -3, and -4 are expressed by murine brain MVEC, and 
TIMP1, -2, and -3 are expressed by human EC isolated from the aorta, iliac artery, and 
coronary artery [80–82]. Additionally, TIMP3 is expressed by murine PMVEC; however, 
TIMP2 and -4 do not appear to be expressed by human PMVEC [83,84]. Interestingly, 
while my data supports the observed lack of TIMP4 expression by PMVEC, it clearly 
demonstrates constitutive Timp2 mRNA expression by murine PMVEC. One potential 
reason for these disparate findings may be due to species differences as well as 
differences in mRNA vs. protein expression as Shen and colleagues examined TIMP2 
protein expression in human PMVEC [84]. 
TIMP expression appears to be differentially regulated under conditions of 
infection and organ injury [53,67,80,81,83,88,90,103]. My observed increase in Timp1 
mRNA expression in septic WT PMVEC is consistent with previous studies in other 
vascular beds. Specifically, treatment of murine brain MVEC with IL1β and TNFα, or 
with homocysteine, have been found to increase Timp1 mRNA expression [80,81]. 
Moreover, TIMP1 levels in serum have been found to be increased in severe sepsis in 
humans [92,93]. Thus, these previous studies combined with the strong increase in Timp1 
expression seen in my dual stimulation in vitro, as well as CLP-sepsis in vivo, strongly 
suggest a potential role for PMVEC-derived TIMP1 in tissue injury and sepsis.  
The decrease in Timp3 mRNA expression in LPS-stimulated WT PMVEC is 
consistent with previous studies, in which TIMP3 expression (mRNA and protein) was 
significantly decreased in murine brain MVEC and PMVEC following treatment with 
IFNγ, IL1β, and TNFα [80,83]. Conversely, my finding that Timp3 mRNA expression 
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increased in PMVEC stimulated with both cytomix and LPS, similar to the observed 
increase in expression in CLP-septic PMVEC, suggests that more intense septic 
stimulation is required to induce Timp3 expression. IL1β and TNFα act synergistically, 
and the combination of both have led to significantly greater inflammation in human 
gingival fibroblasts compared to LPS stimulation or either cytokine alone [117]. In 
human sepsis, as well as murine CLP-sepsis in vivo, both cytokines and LPS are present, 
collectively contributing to excessive inflammation and tissue/organ injury [118,119]. 
Therefore, an in vitro model using both cytokines and LPS may be more reflective of the 
in vivo conditions during sepsis. 
The combination of LPS and IFNγ, IL1β, and TNFα was also found previously to 
maximally upregulate nitric oxide (NO) synthase (NOS) expression in hepatocytes [120]. 
In addition, the combination of LPS and cytokines (TNFα, IL1β and IL6) incubated 
together induced a greater decrease in sarcomere shortening in isolated cardiomyocytes 
compared to stimulation with LPS or individual cytokines alone demonstrating a 
compounding effect [121]. Collectively, my data shows a greater increase in Timp1 
mRNA expression in PMVEC stimulated with a combination of cytokines and LPS than 
PMVEC stimulated with either individually. Timp3 mRNA expression is also induced at 
higher levels in PMVEC stimulated with both cytomix and LPS, which is additionally 
seen in CLP-sepsis in vivo. Overall, combined septic stimulation in vitro more closely 
reflected Timp1 and -3 mRNA expression in PMVEC from in vivo CLP-septic mice, 
suggesting a more effective model than cytomix or LPS individually.  
My examination of metalloproteinase mRNA expression in each septic model 
revealed septic WT PMVEC express significantly greater Mmp9 and Adam17 mRNA 
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levels, whereas Mmp2 and Adam10 mRNA expression levels remain stable. Generally, 
my data are supported by previous studies. For example, stimulation of brain EC with 
TNFα and IL1β selectively upregulates MMP9 production, but does not alter MMP2 
expression [54]. Further, MMP9 expression is also increased in HUVEC following 
bacterial infection and in brain MVEC following viral infection, as well as in patients 
with septic shock [43,57,58]. Additionally, ADAM17 expression has been found to be 
upregulated in murine brain EC following stimulation with multiple pro-inflammatory 
cytokines (i.e. TNFα, IL1β, IFNγ), and in human PMVEC following stimulation with 
LPS [55,56]. Thus, MMP9 and ADAM17 expression by PMVEC appears to be highly 
responsive to inflammatory stimuli suggesting a critical role for these metalloproteinases 
in septic PMVEC dysfunction. 
4.2.2 Metalloproteinase-Dependent Loss of Endothelial Barrier 
Function 
My lab has previously reported that PMVEC barrier function is impaired both in 
vitro and in vivo under septic conditions [8,108,110,114,122,123]. PMVEC activation by 
inflammatory cytokines leads to increased paracellular permeability, predominantly 
through the disruption of inter-PMVEC junctions and actin cytoskeleton-driven PMVEC 
retraction [14,16,20,21,23,31,104,124–127]. There are many mechanisms involved in 
PMVEC barrier dysfunction following sepsis, including VE-cadherin internalization and 
cleavage, as well as actin cytoskeleton polymerization and reorganization 
[14,20,21,23,38,104,128–131]; however, endogenous mechanisms protecting against 
sepsis-induced PMVEC barrier dysfunction are not well understood. 
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Metalloproteinases, which have the ability to cleave multiple extracellular 
proteins associated with inflammation, as well as proteins involved in cell-cell and cell-
ECM interactions, have been found to be expressed by EC and this expression is altered 
under the setting of infection and inflammation, which is supported by my data. 
However, metalloproteinases are regulated at multiple levels, including secretion as 
zymogens and subsequent extracellular activation following secretion [44,47,95]. Thus, 
changes in expression may not be consistently reflected in changes in metalloproteinase 
activity. Mmp9, a soluble metalloproteinase, was consistently upregulated with regards to 
mRNA expression in every septic model, yet total soluble metalloproteinase activity in 
the PMVEC-conditioned media was not altered under septic conditions in vitro. In 
addition, the PMVEC lysate, which includes both membrane bound and intracellular 
soluble metalloproteinases, did not exhibit enhanced metalloproteinase activity under 
septic conditions, even though Mmp9 and Adam17 mRNA expression were both 
upregulated. This disconnect between metalloproteinase expression and activity has been 
recognized, and suggests metalloproteinase activity may be significantly regulated post-
translationally as metalloproteinases are predominantly secreted as inactive zymogens 
[47]. 
My examination of metalloproteinase activity under septic conditions found that 
while global metalloproteinase activity associated with the conditioned media or with the 
cell lysate remained unchanged, combined stimulation of WT PMVEC led to 
significantly increased ADAM17 activity. Importantly, this data demonstrates that the 
observed changes on ADAM17 mRNA expression are reflective of functional changes in 
ADAM17 levels (i.e. increased activity). It is interesting, however, that despite increased 
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ADAM17 activity the total metalloproteinase activity was not significantly increased, 
suggesting that the activity of other specific metalloproteinases may be decreased under 
septic conditions. Further, because the cell lysate was used, it is important to note that 
ADAM17 activity included both the membrane bound protein as well as intracellular 
fraction, although it is unclear which was more active. Biologically, ADAM17 shedding 
events can increase in occurrence without increasing the quantity of membrane bound 
protein via an increase in cellular ADAM17 activity [132].  
Although it is unclear why total metalloproteinase activity does not change under 
septic conditions, my studies clearly demonstrate that inhibition of metalloproteinases 
with synthetic metalloproteinase inhibitors in WT PMVEC under septic conditions 
attenuates septic microvascular barrier dysfunction. BB-94, a potent broad-spectrum 
inhibitor for MMP1, -2, -3, -7, -9, -14 and ADAM17, reduced albumin and dextran flux 
by 50% in cytomix-stimulated WT PMVEC [133]. This is consistent with the literature as 
previous studies found that BB-94 significantly reduced alveolar-capillary leakage in rats 
in pancreatitis-associated lung injury, as well as BBB leakage in rats following either 
acute pancreatitis or methamphetamine treatment [134–136]. My finding that TAPI-2, a 
potent hydroxamate-based inhibitor of MMPs and ADAM17, reduces albumin and 
dextran flux by 40% in cytomix-stimulated WT PMVEC is also supported by previous 
studies [137]. Administration of TAPI-2 was found to significantly attenuate 
bronchoalveolar fluid protein and TNFα levels in mice following hypercapnia acidosis 
[138,139]. 
Interestingly, I also found that GM6001, another broad-spectrum 
metalloproteinase inhibitor, had no effect on microvascular leak in cytomix-stimulated 
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WT PMVEC. This is in contrast to previous studies, which have demonstrated the ability 
of GM6001 to inhibit vascular permeability. Specifically, treatment of HUVEC with 
GM6001 following recombinant TNFα-induced upregulation of metalloproteinase 
activity rescued the increase in permeability as measured by macromolecular flux 
[41,42]. Similarly, treatment of murine cerebrovascular EC with GM6001 following both 
homocysteine injection in vitro and acute liver failure with azoxymethane in vivo resulted 
in decreased microvascular leak due to the reversal of degradation of tight junction 
adhesive protein and F-actin formation through the inhibition of MMP9 [73,74]. Finally, 
previous work from my lab demonstrated that the enhanced basal leak across Timp3-/- 
PMVEC was attenuated by treatment with GM6001. The reason for the apparent 
difference between my current study and previous work on the effects of GM6001 on EC 
barrier dysfunction is unclear. However, one potential mechanism could be due to the 
metalloproteinases expressed and active in the different vascular beds or in different 
models of injury/inflammation. EC from the micro- and macrovasculature have different 
biological properties. For example, EB-albumin leak was significantly higher across 
HUVEC than human PMVEC under basal and septic (LPS or cytomix) conditions [108]. 
HUVEC treated with GM6001 had reduced dextran permeability compared to untreated 
HUVEC [42]. It is unclear which metalloproteinases are responsible for this permeability; 
however, my data suggests they are not inhibited well by GM6001. This current data 
suggest that ADAM17 may be a critical mediator of barrier dysfunction in the lung 
microvasculature during sepsis. This supports a previous study, which demonstrated that 
ADAM17 is involved in the regulation of vascular permeability during LPS-induced 
acute lung injury in murine MVEC in vivo, and its inhibition with GW280264X, an 
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ADAM17-specific metalloproteinase inhibitor, or its absence in Adam17-/- mice, resulted 
in significantly reduced edema formation and vascular permeability [56]. 
One mechanism through which metalloproteinases can mediate loss of PMVEC 
barrier function is through cleaving proteins associated with endothelial adherens and 
tight junctions, such as VE-cadherin, occludin, ZO1, and JAMs as well as other crucial 
adhesive junctional proteins [41,42,56,61–64]. MMP7, ADAM10, and -12 actively 
cleave VE-cadherin [42,62], while MMP2 and -9 are capable of cleaving occludin and 
ZO1 resulting in microvascular dysfunction via increased paracellular permeability 
[61,63]. MMPs also target the components of the surrounding ECM, including 
fibronectin, laminin, and type IV and V collagens, leading to disrupted endothelial–ECM 
interactions and increased vascular permeability [65–70]. Thus, these studies suggest 
increased metalloproteinase activity drives MVEC dysfunction through the proteolytic 
processing of integral MVEC structural determinants (i.e. the ECM), resulting in MVEC 
barrier dysfunction and enhanced microvascular leak. 
In addition to changes in metalloproteinase expression, metalloproteinase activity 
is also regulated by TIMPs. Surprisingly, my data demonstrated that while the overall 
expression of Timps was increased in PMVEC under septic conditions, sepsis was also 
associated with an increase in specific metalloproteinase activity. The four TIMPs have 
overlapping abilities to inhibit metalloproteinases, but also exhibit varying degrees of 
specificity. TIMP1 is secreted as a soluble inhibitor, and predominantly targets MMPs, 
which are mostly soluble [50,95]. My data showed that metalloproteinase activity in the 
conditioned media may be decreasing, which could be indicative of TIMP1 expression as 
TIMP1 is generally found in body fluids (i.e. serum), especially under septic conditions 
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[93,140,141]. Further, TIMP3 is known to inhibit ADAM17, which actively processes 
and cleaves membrane bound pro-TNFα to yield the soluble inflammatory cytokine 
TNFα [142,143]. While the increased ADAM17 activity in the presence of increased 
Timp3 expression is surprising, it is possible that TIMP3 upregulation in septic PMVEC 
in vitro and in vivo is a compensatory mechanism to limit or restrict ADAM17 activity 
and thereby promote maintenance of stable PMVEC barrier function. 
In addition, the observed differences in Timp3 mRNA expression may reflect 
different functions for TIMP3 within the septic microenvironment and during the time 
course of sepsis. For example, under basal conditions, TIMP3 appears to have a critical 
role in promoting PMVEC barrier function, at least in part through regulation of VE-
cadherin localization [83]. TIMP3, however, may also have a role in mediating the initial 
inflammatory response to an infection. Specifically, TIMP3 has been found to inhibit 
shedding of VCAM1 from the surface of aortic EC following treatment with IL1β, TNFα, 
or the phorbol ester PMA [106]. Aortic EC from Timp3-/- mice had increased VCAM1 
shedding compared to aortic EC from WT mice, and this inhibition of VCAM1 shedding 
by TIMP3 was likely through inhibition of ADAM17, as the TIMP3 dependent effect was 
lost under conditions of ADAM17 knockdown [106]. Thus, TIMP3 appears to be a 
critical regulator of MVEC dysfunction following tissue injury/infection, including 
protection against loss of MVEC barrier function and regulation of PMN-PMVEC 
interactions. 
4.2.3 TIMP3 Regulation of PMN-PMVEC Interaction 
My studies demonstrate that endothelial cell adhesion molecules, such as ICAM1, 
VCAM1 and E-selectin, are significantly upregulated in septic WT and Timp3-/- PMVEC. 
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This supports previous studies that found that both ICAM1 and VCAM1 expression on 
the endothelial cell surface was induced by the release of pro-inflammatory cytokines 
from macrophages at the site of infection, including TNFα and IL1β [144–147]. 
Additionally, LPS was found to stimulate translocation of the transcription factor nuclear 
factor κB (NFκB) to the nucleus to initiate transcription of pro-inflammatory cytokines 
and increase endothelial expression of ICAM1, both of which are associated with 
increased endothelial permeability [13,16]. 
Interestingly, my data shows that Timp3-/- PMVEC express significantly less 
ICAM1 on their cell surface under both basal and septic conditions compared to WT 
PMVEC, and this was associated with significantly weaker adhesion to PMN, again, 
under both basal and septic conditions. Previously, ICAM1 deficient mice were found to 
exhibit impaired peritoneal neutrophil migration in response to chemical peritonitis [148]. 
Additionally, mice with a deficiency in both ICAM1 and P-selectin showed a significant 
reduction in neutrophil migration in response to myocardial ischemia and reperfusion 
[149]. Other studies, however, suggest that ICAM1 is not necessary for PMN adhesion to 
EC and extravasation into tissues following infection. Specifically, neutrophil migration 
into the alveolar spaces during acute Streptococcus pneumoniae-induced pneumonia was 
not significantly altered in P-selectin/ICAM1 double deficient mice vs. WT mice [150]. 
Further, lung ICAM1 was required for spontaneous intravascular effector lymphocyte 
entrapment, but not for neutrophil entrapment or emigration following instillation of 
endotoxin [151]. Collectively, my data complements these previous studies and provides 
further evidence to support a role for ICAM1 in regulation of PMN-PMVEC interaction. 
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My studies also provide insight into a potential mechanism regulating PMVEC 
surface ICAM1 expression as the amount of ICAM was significantly less on Timp3-/- 
PMVEC compared to septic WT PMVEC. ICAM1 is constitutively expressed on the cell 
surface of many cell types, including EC, and it is upregulated primarily through 
increased transcription [152]. A number of inflammatory mediators including 
proinflammatory cytokines (IFNγ, IL1β, and TNFα), retinoic acid, ROS and virus 
infection activate ICAM1 transcription under inflammatory and injurious conditions 
[152]. My data demonstrated significant PMVEC upregulation of ICAM1 mRNA and 
protein under septic conditions in vitro, which supports these previous studies. However, 
this data also suggests that Icam1 mRNA expression may not always correlate with cell 
surface ICAM1 levels. Specifically, Timp3-/- PMVEC stimulated with cytomix had 1.4-
fold more expression than WT PMVEC; LPS had 1.3-fold less expression than WT 
PMVEC; cytomix and LPS had 4-fold more expression than WT PMVEC. However, cell 
surface ICAM1 levels were similar in PMVEC under each condition, with a significant 
decrease observed in Timp3-/- vs. WT PMVEC. In addition, Icam1 mRNA expression was 
upregulated the most in PMVEC stimulated with both cytomix and LPS, and the least in 
PMVEC stimulated with LPS. However, cell surface quantity of ICAM1 was upregulated 
approximately the same under each septic condition. 
One mechanism regulating cell surface ICAM1 may be proteolytic cleavage 
[153,154]. For example, MMPs have previously been found to shed ICAM1 from the cell 
surface under inflammatory conditions [153]. Additionally, human leukocyte elastase, 
which has been found to cause tissue destruction in a number of inflammatory diseases, 
also sheds ICAM1 from the cell surface [154]. However, treatment with the broad-
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spectrum metalloproteinase inhibitors GM6001, BB-94, and TAPI-2 had no effect on 
Timp3-/- cell surface ICAM1, which suggests that the decreased ICAM1 on Timp3-/- 
PMVEC was not due to increased metalloproteinase activity. TIMPs have also been 
found to have metalloproteinase-independent functions. For example, TIMP3 inhibits cell 
proliferation, binding directly to VEGFR2 on EC and blocking VEGF-VEGFR2 
interaction, thereby inhibiting phosphorylation of VEGFR2 and downstream signalling 
leading to decreased EC proliferation [95]. Further, VEGFR2 activation in response to 
VEGF was also reduced by overexpression of a mutant TIMP3 that lacked the ability to 
inhibit MMPs suggesting that TIMP3 inhibition of VEGF signaling is a 
metalloproteinase-independent function [95]. Similarly, TIMP3 also binds the ANG II 
type 2 receptor, and the presence of both inhibits HUVEC proliferation and angiogenesis 
through inhibition of PKC and endothelial NOS (eNOS) [155].  
Although there are no known mechanisms to explain the reduced ICAM1 on the 
cell surface of Timp3-/- PMVEC, one proposed mechanism could involve ADAM17. 
Previous studies have targeted ADAM17 to shed VCAM1 and ICAM1 from the cell 
surface of EC. PMA stimulation of heart and aortic EC induced VCAM1 shedding via 
ADAM17 [78]. Further investigation determined that PMA stimulated aortic EC from 
Timp3-/- mice had increased VCAM1 shedding compared to stimulated WT mice, 
suggesting TIMP3-dependent inhibition of ADAM17 [106]. However, my data does not 
support this due to the lack of observed differences in ADAM17 activity between WT 
and Timp3-/- PMVEC lysate, as well as the lack of observed differences in cell surface 
ICAM1 on Timp3-/- PMVEC treated with GM6001, BB-94, or TAPI-2, suggesting a 
metalloproteinase-independent mechanism. 
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4.2.4 Role of TIMP3 in TIMP/Metalloproteinase Balance 
In general, the primary function of TIMPs is thought to be inhibition of 
metalloproteinase activity [47,95,96]. Further, shifting the balance between TIMPs and 
metalloproteinases in favour of TIMPs is thought to regulate and reduce inflammation 
and injury, while a shift in favour of metalloproteinases is thought to cause organ damage 
and dysfunction [46,90,93,98,100,101]. For example, Timp3-/- mice have been found to 
have decreased bronchiole branching and enhanced activity of MMPs throughout lung 
development, leading to erratic focal ECM proteolysis [100,101]. In addition, lung 
inflammation from bleomycin-induced injury persisted nearly four-times as long in 
Timp3-/- mice, and was associated with upregulated MMP activity and greater neutrophil 
chemotactic activity compared to WT mice [98]. In contrast, mice with a specific MMP 
deficiency tend to have reduced morbidity and mortality in models of infection and 
injury. Mmp9-/- mice were resistant to endotoxin-induced shock following endotoxemia 
[156]. Bacterial endotoxin-induced systemic inflammation was considerably repressed in 
mice lacking MMP3 [157]. MMP8 and -13 deficient mice were highly resistant to lethal 
effect of LPS and CLP, with the latter being associated to reduced TNF release [43]. 
Interestingly, metalloproteinase activity data in Timp3-/- PMVEC in the current 
report shows a shift in favour of TIMPs. Soluble metalloproteinase activity decreases in 
Timp3-/- PMVEC basally, suggesting that TIMP1, a strong inhibitor of soluble MMPs, is 
basally expressed at a sufficient quantity to inhibit these MMPs. However, I only 
assessed the expression of a handful of metalloproteinases, and it is possible that there 
could be differences in expression of other metalloproteinases (i.e. decreased expression), 
which would account for the observed decrease in activity under basal conditions. Total 
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metalloproteinase activity in Timp3-/- PMVEC lysate did not differ vs. WT lysate, and 
one possibility is that other TIMPs may compensate for the lack of metalloproteinase 
inhibition by TIMP3 in the Timp3-/- PMVEC. My studies, however, found no evidence of 
compensation in Timp1 and -2 mRNA expression in Timp3-/- PMVEC basally, which 
suggests that compensation is not involved. 
Further, there is the potential for redundancy in the inhibition profiles between 
TIMPs. However, while in vitro studies have demonstrated overlapping 
metalloproteinase inhibition profiles (i.e. both TIMP1 and TIMP3 have been implicated 
in the regulation of MMP7 activity and thus, in the absence of TIMP3, TIMP1 may be 
able to inhibit MMP7 activity even without evidence of increased expression), there are 
differences that exist between TIMPs in their ability to inhibit specific 
metalloproteinases, especially ADAMs [79,95,97]. For example, TIMP1 does not appear 
to be an effective inhibitor of the membrane type MMPs (MT-MMPs; MMP14, -15, -16, 
-17, -24, and -26) [50]. Additionally, TIMP3 is unique from other TIMPs as it is a very 
strong inhibitor of ADAMs and, currently, is the only known inhibitor of ADAMTSs 
[50]. As such, it is surprising that ADAM17 activity was not significantly increased in 
Timp3-/- PMVEC basally. Further, this lack of change in ADAM17 activity in Timp3-/- 
PMVEC makes it unclear whether ADAM17 is responsible for the previously reported 
increase in basal microvascular albumin flux in Timp3-/- PMVEC as a decrease in 
ADAM17, as well as ADAM10, have been previously demonstrated to reduce vascular 
permeability [42,56,83]. However, one caveat is that my analysis of ADAM17 expression 
was in total cell lysate and not solely cell membrane associated. As such, it is unclear if 
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ADAM17 activity was seen intracellularly in WT PMVEC from ADAM17 being 
processed or transported to the cell membrane. 
4.3 Limitations and Future Directions 
4.3.1 Study Limitations 
Many of my experiments were done entirely in vitro, and thus, under static 
conditions. However, in an in vivo setting, several external forces, such as hemodynamic 
stimuli including shear stress and changes in vessel size can affect PMVEC physiology 
and responses to inflammatory stimuli (i.e. sepsis). Modulation of blood flow is achieved 
by the release of vasoconstrictors (i.e. angiotensin-converting enzyme, endothelin) and 
vasodilators (i.e. NO, prostacyclin) in order to regulate vascular resistance and systemic 
blood pressure [15,17]. Adhesive junctional proteins, such as VE-cadherin, may also act 
as flow sensors and transmit intracellular cues that signal the cell to react to changing 
conditions [21]. Due to technological limitations, I was not able to replicate a flow model 
that PMVEC would encounter in their native conditions. However, my use of multiple in 
vitro models of septic stimulation created various environments for the endothelium to 
respond to, one of which appears to be a strong representation of a septic environment in 
vivo based on my ex vivo expression analysis. Overall, I believe that the use of multiple 
models strengthened my in vitro analysis, and was also supported by direct ex vivo study 
of PMVEC isolated from septic mice. 
Although TNFα, IL1β, and IFNγ are seen in human sepsis, they are considered to 
be pro-inflammatory cytokines, and not sepsis-specific. Previous studies have identified 
significant increases in several other cytokines, including monocyte chemotactic protein 
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1, IL6 and -8, granulocyte colony-stimulating factor, hepatocyte growth factor, and 
macrophage inflammatory protein 1β, in plasma from patients with severe sepsis [158]. 
Using a mixture of these sepsis-specific cytokines, in conjunction with the current 
cytomix, may create a more accurate model of sepsis in vitro. 
Additionally, PMVEC were cultured on 1% gelatin coated transwell inserts and 
wells in order to mimic an extracellular matrix for the cells to adhere to. The ECM, 
however, is a complex network, composed of many different components in vivo 
including collagens, gelatin, fibronectin, laminin, and elastin. These many components 
mediate PMVEC-ECM interaction and downstream signalling through integrins, 
releasing cryptic ECM fragments, which activate cell signalling and releasing sequestered 
growth factors [49,101]. In order to mimic physiological conditions present in vivo, a 
variety of ECM components, including collagens, elastin, proteoglycans, and fibronectin, 
can be used in cell culture. Furthermore, the glycocalyx is known to be an important 
regulator of endothelial function, forming a significantly thicker pulmonary endothelial 
surface layer compared to other regions in the systemic circulation [25]. This endothelial 
surface layer is critical to inflammation, barrier function and mechanotransduction. 
Specifically, it regulates the exposure of EC surface adhesion molecules, acting as a 
barrier to neutrophil adhesion and extravasation [25]. Metalloproteinases have been 
shown to have the ability to cleave the glycocalyx, which is predominantly cleaved by 
heparanase; however, the glycocalyx is only observed in vivo and appears to be absent in 
vitro [25,159]. 
Further, while my studies assessed the PMVEC expression of each TIMP under 
basal and septic conditions, it lacked a comprehensive analysis of metalloproteinase 
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expression. Specifically, my study focused on three MMPs and two ADAMs; however, 
metalloproteinases are an incredibly diverse group of enzymes. Finally, while I assessed 
metalloproteinase and Timp mRNA expression, I did not examine metalloproteinase and 
TIMP protein levels specifically due to a lack of available suitable antibodies. This 
analysis of metalloproteinase activity was used as a surrogate for examining 
metalloproteinase and TIMP protein levels as the balance between these components is 
critical to metalloproteinase activity; however, further analysis of the activity of specific 
metalloproteinases and the use of specific inhibitors is required. 
4.3.2 Future Directions 
In future studies, barrier dysfunction in septic WT PMVEC must be further 
characterized in vitro to define the TIMP-dependent mechanisms promoting normal 
PMVEC barrier function and protecting against septic PMVEC barrier dysfunction. Thus, 
comprehensive expression and protein analysis of other members of the MMP and 
ADAM families must be investigated combined with the use of specific activity assays 
and inhibitors. Further, the use of PMVEC with genetically modified expression of 
metalloproteinases (i.e. PMVEC isolated from mice genetically deficient, use of siRNA) 
and more specific MMP/ADAM inhibitors will be required to comprehensively assess 
their functional role. It will also be critical to utilize mice lacking specific 
metalloproteinases and TIMPs to confirm my in vitro studies using in vivo models of 
sepsis. 
The reduced quantity of cell surface ICAM1 in Timp3-/- PMVEC should also be 
further addressed by determining total (cytosolic combined with cell surface) ICAM1 
protein expression. If total ICAM1 protein is significantly reduced compared to WT 
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PMVEC, it suggests there is a disruption in the translational process, whereas if total 
ICAM1 protein in Timp3-/- PMVEC is similar to WT PMVEC, it suggests that the protein 
is effectively being synthesized, but that localization to the cell surface under basal 
conditions is impaired. Interestingly, while the mechanisms mediating the decreased 
ICAM1 on the cell surface of Timp3-/- PMVEC is unknown, it is important to note that 
the increase in ICAM1 on the cell surface of Timp3-/- PMVEC under septic conditions 
does suggest that Timp3-/- PMVEC have the ability to produce and localize ICAM1 
protein to the cell surface. 
In addition, while these studies utilized synthetic global metalloproteinase 
inhibitors, the use of rTIMP3 is required to confirm the specific role of TIMP3 in both 
microvascular leak as well as PMN-PMVEC interaction. This is important as injection of 
rTIMP3 has been reported to decrease vascular leak across the blood-brain barrier in a 
model of traumatic brain injury [80]. 
This investigation also focused solely on the metalloproteinase-dependent role of 
TIMPs in PMVEC barrier dysfunction. There is, however, evidence for several 
metalloproteinase-independent mechanisms. TIMPs have been found to interact directly 
with cell surface receptors to activate the receptor and initiate cell signalling (i.e., TIMP1 
binds CD63 and β1 integrin to promote epithelial cell proliferation and inhibit apoptosis) 
[160]. Further, TIMP3 inhibits angiogenesis by binding to the VEGF receptor and 
blocking VEGF-VEGFR2 interactions [88,90]. Similarly, TIMP3 also binds the ANG II 
type 2 receptor, inhibiting HUVEC proliferation and angiogenesis through inhibition of 
PKC and eNOS [155]. Thus, for example, future characterization of the VEGF signalling 
pathway in WT and Timp3-/- PMVEC under basal and septic conditions would allow for 
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direct examination of the role of TIMP3-dependent VEGFR2 phosphorylation in basal 
EC permeability and septic EC barrier dysfunction. 
Solely male murine PMVEC were used for the current study; however, there is 
much evidence of sex specific differences in human sepsis (i.e. septic females are less 
susceptible to organ dysfunction and death). Men are more likely to have a 372 T/C 
genetic polymorphism on the TIMP1 gene, which is associated with a higher risk of 
severe sepsis and mortality [161]. Further, plasma levels of MMP3 were significantly 
higher in male patients with severe bacterial sepsis compared to female patients [162]. 
Finally, men with severe bacterial sepsis represented a greater percentage of carriers of 
MMP3 single nucleotide polymorphism allele 6A [162]. Thus, it would be interesting to 
examine whether there are differences in the roles of metalloproteinases and TIMPs. 
Preliminary mRNA expression data suggests that overall basal expression of Timps, 
metalloproteinases, and cell surface proteins are similar in both sexes; however, there are 
some trends towards sex-linked differences (Figure 4-1).  
Lastly, all experiments were conducted using murine cells, and as such, human 
cells must be employed in future studies to investigate this endogenous TIMP-dependent 
mechanism promoting basal PMVEC barrier function in vitro, as well as potential 
involvement in septic PMVEC barrier dysfunction. These studies would provide an 
opportunity to assess in human PMVEC the molecular mechanisms regulating normal 
and septic microvascular permeability that I have identified in murine PMVEC, which 
will give further insight regarding the physiological relevance of these findings, as well 
as provide strong clinical relevance. 
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Figure 4-1: Septic changes in TIMP and metalloproteinase expression are different 
in female vs. male PMVEC. Compared to naive male mice, Timp and metalloproteinase 
mRNA expression is relatively similar in naïve female mice. Compared to 4h CLP male 
mice, Timp and metalloproteinase mRNA expression is significantly altered or appears to 
be altered in 4h CLP female mice; specifically, Timp1, -2, -3, Mmp2, -9, Adam17, Icam, 
Vcam, Sele. * p<0.05 vs. male, Two-Way ANOVA followed by a Bonferroni post-hoc 
test, n=4-8. 
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4.4 Summary and Conclusions 
In conclusion, I have identified a disruption in the TIMP/metalloproteinase 
balance, leading to increases in specific TIMP and metalloproteinase expression and 
metalloproteinase activity associated with septic PMVEC barrier dysfunction. This septic 
PMVEC barrier dysfunction is based on a metalloproteinase-dependent mechanism, 
potentially mediated through ADAM17, resulting in increased microvascular 
permeability. In addition, Timp3-/- PMVEC have reduced ICAM1 on their cell surface, 
which may be associated with impaired PMN recruitment. Based on my results, I believe 
PMVEC-derived TIMPs support normal pulmonary microvascular endothelial barrier 
function via metalloproteinase-dependent mechanisms, through the direct inhibition of 
metalloproteinase activity, but also through metalloproteinase-independent mechanisms, 
via regulation of PMN-PMVEC interactions (Figure 4-2). A better understanding of the 
TIMP-mediated endogenous protective mechanism against septic PMVEC barrier 
dysfunction would support new therapeutic interventions in human sepsis and related 
septic organ dysfunction, as well as help eliminate PMVEC dysfunction in other vascular 
diseases. 
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Figure 4-2: Disruption in the balance between metalloproteinases and tissue 
inhibitors of metalloproteinases leads to PMVEC activation and dysfunction. (A) 
Septic PMVEC barrier dysfunction is based on a metalloproteinase-dependent 
mechanism, resulting in increased microvascular permeability. (B) PMN-PMVEC 
adhesion increased under septic conditions due to activation of cell adhesion molecules. 
(C) In the absence of TIMP3 (Timp3-/-) cell surface ICAM1 is reduced on the cell surface 
under basal and septic conditions, which may be associated with impaired PMN 
recruitment; however, it appears to be through a metalloproteinase-independent 
mechanism. 
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